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ABSTRACT
ENGINEERING OF TWO-COLOR ATP-BINDING CASSETTE BIOSENSOR
PROTEINS FOR DISCOVERY OF NOVEL SUBSTRATES AND MODULATORS
BREMANSU OSA-ANDDREWS
2018
ATP-binding cassette (ABC) transporter proteins are a vast, ubiquitous superfamily of
proteins most of which unlock the energy from ATP-binding and hydrolysis to influx or
efflux a wide spectrum of structurally dissimilar substrates across cell membranes. All
eukaryotic ABC transporters including P-gp and MRP1 only exist as efflux pumps whose
prominent expression in cells is associated with multidrug resistance of antiretrovirals,
antiepileptics, antimalarials and anticancer agents. P-gp and MRP1 reduce the
bioavailability and efficacy of chemotherapeutic drugs by actively pumping out these
drugs, thereby, leading to poor clinical outcomes during chemotherapy. Due to their
clinical importance, profiling of the interaction of MRP1 and P-gp with therapeutic drugs
is pertinent. Here, we developed an innovative two-colorMRP1 and P-gp biosensors by
fusing the transporter with green fluorescent (GFP) and red fluorescent (RFP) proteins.
These biosensors exhibit large dynamic FRET changes in response to movements of the
transporter upon substrate-binding and is useful for high throughput screening for
potential modulators. Following a steady-state FRET screening, the two-colorMRP1
biosensor identified 10-anticancer drug-hits of 40, and the two-color P-gp detected 6 hits
of 50 antitumor drugs, which are ligands and potential substrates of their respective
transporters. In the absence of a single known high throughput screening for detection of
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drug-ABC transporter interaction, our coupled ensemble FRET model is transformative
as it holds promise for fluorescent plate reader-based high throughput screening for
substrates and ligands of these transporters. Future projects will focus on vesicular
transport-coupled LC-MS/MS assay to verify the ABC transporter-substrate status of the
anticancer drug-hits discovered in the present study.
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CHAPTER 1
INTRODUCTION
Scope
The general goal and significance of the present study is to develop an ATPbinding cassette (ABC) transporter protein biosensor, suitable for the profiling of
substrates and ligands using fluorescence spectroscopy. This section opens by exploring
the literature regarding membrane proteins and transport proteins in general and their
significant role in the movement of solutes in and out of cells. The mode of transport by
the proteins as well as the source of energy utilized, if needed for the transport process.
Of interest in this segment of the present treatise is the ubiquity of ABC transporter
proteins in all phyla; bacteria, archaea bacteria and eukaryotes. The section then looks at
the types of ABC transporters in prokaryotes and eukaryotes. The general structural
organization of ABC transporter proteins are described in detail as it is core to the
methodological strategy for the current project. The distribution, physiological functions
and implications of the transport activity of ABC transporter proteins are expounded
next. The significance of ABC transporter proteins regulating multidrug resistance
(MDR) and the clinical correlation this has on health and diseases are delved into as it
relates to the current project. The section then makes an argument for the significance of
the current project by explaining the need for profiling of drug-ABC protein interactions.
Next, the methodological tools which have been employed for the identification of
substrates of key ABC transporter proteins, P-glycoprotein and Multidrug resistance
protein-1 (MRP1) are described. The section then describes the literature regarding
fluorescence spectroscopy, the key tool for Fluorescence based procedures in the present
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project. This chapter concludes by providing a relevant rationale for carrying out the
present work and the potential adaptation of the methods and our work and utilization of
our findings of by members within the ABC transporter field and beyond.

Membrane transport proteins
Membrane transport proteins are primarily responsible for translocating materials
across cell membranes down or against an electrochemical gradient. Three major
membrane transport proteins exist in nature including channel proteins, secondary active
transporters and primary active transporters which includes ATP-binding cassette (ABC)
transporter proteins. Channel proteins are involved in an energy-independent facilitated
diffusion down a concentration gradient, of solutes across cell membranes, while
secondary active transporters mediate the uniport, symport and antiport of substances,
harnessing stored ion-gradient energy [1, 2]. The source of energy, if used by transport
proteins is the key feature which dichotomizes the kind of transport proteins they are.
Primary active transporters, like ABC transporter proteins couple transport to ATP
hydrolysis by unlocking the energy from the hydrolytic reaction to power transport of
solutes across the phospholipid bilayer. On the other hand, two types of membrane
proteins are attached to the lipid bilayer with varying degrees of strength; Peripheral
membrane proteins attach loosely to the bilayer and integral membrane proteins are
permanently associated with the cell membrane (Figure 1.1). ABC transporter proteins
are a classical integral, transmembrane protein core [3].
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Figure 1.1 Schematic presentation of biological membranes.
Phospholipid bilayer creates a hydrophobic transmembrane core and hydrophilic extracellular
portions and intracellular divisions. Peripheral membrane proteins are loosely attached, and
integral membrane proteins are tightly connected and spans the hydrophobic core [3].

ATP-binding cassette transporter proteins
Adenosine triphosphate (ATP) -binding cassette (ABC) transporter proteins are a
ubiquitous superfamily of integral membrane proteins characterized by multimembrane
spanning domains and cytoplasmic subtended ATP-binding [4]. Majority of the members
of the ABC transporter proteins actively utilize the energy from an of ATP-dependent
hydrolysis to shuttle a broad spectrum of molecules across biological membranes [5]. The
diversity of substrates translocated by ABC transporters span solutes, anions, amino
acids, sugars, vitamins and many other structurally unrelated molecules. ABC
transporters are evolutionarily conserved proteins which are found in all phyla, spanning
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prokaryotes, archaea-bacteria and eukaryotes. In prokaryotes, some ABC proteins are
known as importers where they function to uptake nutrients into the cell, while others,
exporters, efflux molecules out of cells [6]. Eukaryotic ABC transporters are exclusively
exporters.

Bacterial ABC transporters
ABC importers are one of the two types of bacteria ABC transporters. They
mainly regulated the influx of a wide variety of essential nutrients needed for bacterial
survival. The nutrient needs of prokaryotes are diverse and quantitively disparate and
require efficient supervision [7]. Carbon and nitrogen sources are required in large
amounts whereas only trace quantities of transition metals can be accommodated by
bacterial cells. Efficient regulation of the uptake of these nutrients which widely includes
peptides, amino acids, saccharides, vitamins, ions, organic and inorganic substances, in
just the right amounts are essential to the functions of ABC importers [2]. The uptakerole played by ABC importers is classically vital for the survival of pathogenic bacteria in
the nutrient-scarce environment of host mammalian organism. Animal infection models
have been used to show that mutations in zinc, iron, magnesium-uptaking ABC importers
impacts negatively on the virulence of the bacteria. This has been shown particularly in
pathogens such as vibrio cholerae and salmonella enterica strains. In addition, bacterial
ABC importers are involved in cell to cell communication, osmoregulation and
internalization of signaling molecules [8, 9].
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Bacterial ABC exporters are similar systems as found in eukaryotes. They
mediate efflux transport of a host of structurally dissimilar drugs and toxins from the
bacterial cell. ABC exporters in bacteria confer multidrug resistance (MDR) to several
antibiotics by pumping these drugs out of cells. The LmrA transporter found in
Lactobacillus lactis is a classic example of MDR conferring efflux pump in prokaryotes
[10]. ABC exporters also participate in the secretion of certain proteins particularly the
sec independent type I protein secretion system [11]. Bacterial ATP-dependent exporters
are also involved in lipid translocation, biosynthesis of lipopolysaccharides and delivery
of precursors for protein glycosylation as shown in Campylobacter jejenum (Pg1K) and
Escherichia coli (MsbA) [12, 13].

Eukaryotic ABC transporters
Eukaryotic ABC transporters lack the importing and cellular-uptake activity of
bacterial transporters, with only efflux function. ABC transporters in eukaryotes mediate
the efflux of solutes and ligands from the interior to the exterior of the cell or to the
interior of organelles. Some ABC transporters such as multidrug resistance protein 1
(MRP1) are exclusively eukaryotic without any discovery yet made in prokaryotes. Not
all eukaryotic ABC transporters are classical efflux pumps. The cystic fibrosis
transmembrane conductance regulator (CFTR, ABCC7) and sulfonyl urea receptor (SUR
or ABCC8) which are associated with cystic fibrosis and diabetes, are ATP-reactive
protein channels but do not directly transport drugs [14-16]. At least three clinical MDRmediating human ABC transporters have been characterized; P-glycoprotein, MRP1 and
Breast cancer resistance protein (BCRP) [17, 18]. These human transporters have been
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found to be are prominently expressed in tumor cells have been found to extrude a broad
spectrum of hydrophobic substrates including anticancer agents. The scope of the current
work remains within exploring the development of methods for identification of
substrates of human ABC transporters.

Structural organization of ABC transporter proteins
ATP-binding cassette transporter proteins belong to the largest superfamily of all
transporter proteins. All ABC transporter proteins share a similar architecture. They
consist of four domains, two membrane-spanning domains (MSD1 and MSD2) and two
nucleotide binding domains (NBD1 and NBD2) [2, 14]. Some ABC proteins have an
extra N-terminal membrane spanning domain (MSD0) but the utility of this domain is yet
unclear. In most eukaryotes, all four domains are in a single polypeptide chain. Each
MSD consists of α-helices which span the lipid bilayer membrane multiple times. The
two MSDs combine to form the substrate translocation pathway. The NBDs extend into
the cytoplasm where they bind and hydrolyze ATP during catalytic activity. In
eukaryotes, the MSDs and the NBDs are connected by cytoplasmic loops unlike in
bacterial ABC importers where they are separate polypeptides [19]. The MSDs and the
NBDs in eukaryotes fuse together at the core creating the substrate binding pocket which
consists of amino acids that recognize a great diversity of structurally unrelated
compounds and ligands. In prokaryotic exporters, one MSD and one NBD fuse to form a
half-transporter which needs to dimerize with the other half prior to functional catalytic
activity by the transporter.
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The NBDs are the most evolutionarily conserved region in the ABC superfamily
as they all bind to a common nucleotide. This is pertinently due to the presence of three
short motifs in the primary sequence of the NBDs; Walker A motif consisting of
GXXGXGKS/T, X may be variable and walker B motif, hhhhD, where h represents
hydrophobic amino acid and motif C (signature C) which is the most conserved sequence
of all ABC transporters (Figure 1.2) [6]. Walker A is involved with binding of the β-γ
phosphates of ATP to the Gly loop o γ-phosphate linker. The highly hydrophobic walker
B is responsible for Mg2+, a needed metal ion for ATP hydrolysis. Motif C is called the
signature sequence since it is useful in putative discovery of new ABC proteins [20].
These walker A and B motifs of the primary sequence of the NBDs is generally what the
‘AB’ of ABC proteins refers to. In contrast, primary sequence and structural composition
of the MSDs are uniquely varied and this reflects the broad substrate diversity of ABC
transporters [21, 22].
Studies conducted on mouse P-gp and bovine MRP1 reveal two conformations
the NBDs of ABC transporters prior to and during a catalytic activity; the substratedeficient open and substrate-bound closed conformations [23, 24]. It is thought that the
binding of the substrate brings the NBDs, whose affinity for ATP increases come into
proximity. Functional characterization of bovine MRP1 shows that substrate binding
pulls the NBDs to 0.2 Ǻ closer (Figure 1.3) to each other prior to nucleotide binding [23].
This process elicits conformational changes in the MSDs which create space for the
substrate to be pumped out through the substrate translocation pathway. This alternating
switch in conformations between the open and close, reflects the rationale for the cloning
strategy employed in the present study.
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Figure 1.2 Structure of the NBD of a typical ABC transporter.
Primary and secondary structure of HisP. α-helices are represented as rod-shapes and the arrows
stand for β-sheets. The conserved motifs Walker A, B and motif C (the signature sequence) are
underlined. The γ-phosphate linker is shown as purple dotted lines [20].
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Figure 1.3 Structure of bovine MRP1
The structure shows LCT4- recognition and binding in the binding pocket of the transporter. On
the left are the ligand-free tertiary structures (top is PDB tertiary structure, bottom is a schematic
structure) in the open conformation of the NBDs. On the right are the LTC4-bound closed
conformation in both PDB structure (top) and schematic (bottom) [23]. The predominantly
yellow molecule in the binding pocket is the LTC4. The NBDs shift 0.02 nm closer to each other
following substrate binding.
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Catalytic mechanism of ABC proteins
Following extensive studies of the structure of P-gp, the ATP-switch model has
been postulated [4]. The ATP-switch model employs the possible substrate-loving ‘open’
state, the low substrate affinity-closed conformations of the NBDs and ATP hydrolysis to
interpret the catalytic mechanism of transport [25]. In the absence of a substrate, the
NBDs are thought to distant from each other, but they come into proximity once a
substrate binds to the active site. This open and closed conformations of the NBDs have
been corroborated from recent studies on cryoelectron-microscopic structure and
substrate affinity of the bovine MRP1. In the bovine MRP1 study, they found that the
NBD-pair moves 0.02 nm closer in the presence of leukotriene C4 (LTC4) [23]. ABC
proteins enact their function essentially by switching between the two conformational
NBD-states.
The detailed steps which describe the transport mechanism of ABC proteins are
expounded as follows, starting from the substrate-loving ‘open’ stance; substrate binding,
closure of NBDs, ATP binding, substrate evacuation, ATP hydrolysis open conformation
regained. Substrate-binding at the active site orchestrates conformational changes in
association with cytoplasmic loops to gives rise to increased affinity of the NBD1 for the
ATP-molecule. Of note in the mechanism is that in the open NBD conformation, the
MSDs are also in a cytosolic-facing open conformation which makes the substratebinding site accessible by molecules. Binding of ATP elicits a closing-movement of the
NBDs toward each other, a pull strong enough to rearrange the MSDs to outward-facing
stance. This open stance of the NBDs in conjunction with proximal NBDs forms the
substrate-translocation pathway through which the substrate is eventually pumped out.
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The substrate-dependent closed-proximity of the NBDs is thought to be a reversible
transient state which reduces the affinity of the transporter for the substrate and hence,
substrate evacuation. One key element in the mechanism is the inevitable ATP hydrolysis
which destabilizes the closed conformation of the NBDs provides the energy required
from release of adenosine diphosphate (ADP) and phosphate (Pi) to actively pump out
the substrate.
The occurrence of hydrophilic amino acid sequence in the upper half of the
binding pocket and hydrophobic groups in the lower half is responsible for the substrate
promiscuity [26]. Consequently, several chemically dissimilar ligands have been
discovered as substrates of important ABC proteins (figure 5). In the present study, the
ATP-switch movement of the NBDs was harnessed to design and attach fluorophores to
them for FRET-based analysis to identify potential substrates of ABC transporters.

Physiological functions of ABC transporter proteins
Generally, there are three classes of ABC proteins and which class a protein
belongs to, defines their functionality. Class-2 ABC proteins, which do not mediate ATPhydrolytic transport of solutes contain nucleotide binding domains but lack the membrane
spanning domains and are associated with biological processes such as DNA repair
instead of transport [27]. However, class-1 and class-3 ABC proteins are usually
transporters involved in transport of ligands across plasma membranes through ATPdependent hydrolysis [20]. A few ABC transporters are not transporters in particular,
even though they stimulate ATP hydrolytic process to allow the passage of ions. CFTR, a
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Cl- channel is the one of the commonest ion channels which regulates movement of
chloride ions. Sulfonylurea receptors (SUR) are ABC proteins which regulate potassium
channels in an ATP-dependent process [28]. Some classic ABC transporters such as P-gp,
in addition to mediating translocation of solutes, also regulate chloride channels [29].
Most ABC transporters mediate the evacuation of endogenous molecules and
xenobiotics from the inside to extracellular spaces across plasma membranes. ABC
transporter proteins demonstrate a high degree of substrate diversity, being responsible
for the efflux of a wide variety of structurally unrelated compounds as shown in figure 5.
These ABC transporters are involved in several physiological functions such as tissue
defense against exogenous insults and maintenance of balance between antioxidant and
free radical concentrations (the MRPs) detoxification (P-gp), absorptive and secretory
activities (ABCBs and MRPs), antigen presentations (ABCB2 and ABCB3) and lipid
metabolism (ABCA1 and ABCGs) [26, 30, 31]. Substances transported by ABC proteins
include amino acids, lipids, hydrophobic compounds, metals ions, saccharides, and a host
of others. The mode of transport of many solutes is through conjugation with glutathione
(GSH) such as estradiol glucuronide or to sulphate such as estrone sulfate, E2SO4 [24].
GSH is the most abundant non-protein thiol in the cell, mediating the thiol-redox status of
cellular processes. Therefore, efflux of glucuronide conjugates in both the oxidized and
reduced forms of glutathione (Gamma-Glu-Cys-Gly), indicates ABC transporters are
involved in the regulation of other physiological and pathophysiological processes
glutathione is associated with [32]. Figure 1.4 shows a schematic diagram of the singular
export of LTC4 as well as the co-export of vincristine from cells.
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ABC proteins are vital in several biological process so mutations in their genes
lead to genetic diseases such as cystic fibrosis, bile defects, cholesterol transport
disorders and neuro-degenerative diseases [33]. These modes of transport are particularly
characteristic of multidrug resistance associated protein-1. The tissue distribution of
many ABC transporters depicts their role in tissue defense and protection. There are fifty
known human ABC transporters out of which fourteen are known to be associated with
diseases [4]. The ABC transporters P-gp, MRP1 and BCRP play a key role in the
efficacy, disposition and toxicity of therapeutic agents[32, 34-37]. Figure 1.5 displays the
vast spectrum of substrates exported by ABC transporters.

Figure 1.4 ATP-dependent ABCC/MRP transport model depiction.
The ABC transporter effluxes LTC4 out of the cell (right). The co-transport of vincristine and
GSH by the transporter is being depicted on the left.
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Figure 1.5 Substrate diversity of ABC transporters.
The transporters pump out a vast number of structurally unrelated endogenous and exogenous
compounds.

Absorption, Distribution, Metabolism and Excretion (ADME)
Absorption of ingested drugs is a key pharmacokinetic index of cells lining the
small intestines. In the apical and the basolateral sides of the lumen of the small intestines
are lined both influx transporters and efflux pumps, notably MRP1, P-gp and BCRP.
Digested food from the gut is absorbed from the lumen of the small intestines through
tight junctions into the blood to be carried through-out the body [31, 38-40]. Animal
studies have shown the importance of ABC transporters in the absorption of nutrients
from food and administered drugs. The prominent expression of these ABC transporters
at this brush border membrane suggest they can pump out drugs back out into the lumen
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of the small intestines, affecting the bioavailability of these drugs. This underscores the
pharmacokinetic significance of ABC transporters in restricting the extent of absorption
of drugs. Of the three aforementioned ABC transporters which govern absorption, MRP1
is the most well studied for that specific physiological function [4, 25, 41].
Drug distribution is critical for their effectiveness as they need to be shuttled
precisely from the location of administration to target tissues. The prime target tissue for
many therapeutic drugs is the brain and this makes the blood brain barrier (BBB) An
important site. Contrary to earlier notion that lipophilicity is all that was required for
drugs to traverse the BBB, many hydrophobic drugs have been found to display impaired
BBB penetration [4, 42]. It is now thought that ABC transporters and their export
activities could be blamed for poor BBB permeability of drugs. These findings
underscore the importance of ABC proteins, particularly MRP1, MRP2, BCRP and P-gp
in protecting delicate tissues such as those of the central nervous system (CNS).
Drug metabolism is generally impacted by drug absorption and distribution. The
less the amount of drugs accumulated in cells, the less will be metabolized. Drug
excretion occurs in the kidneys and liver which are notable for detoxification [43, 44].
Hepatocytes for instance are lined in the sinusoidal (basolateral) and the canaliculi
(apical) side with influx and efflux transporters [45]. Hepatocytes containing canalicular
lined efflux pumps such as P-gp abstract and transport drugs from circulation and channel
them into the bile to be excreted. The integrity of these ABC transporter and the
efficiency of this process influences the extent of drug excretion. These can significantly
impact on drug toxicity as well. P-gp is noted for transport of cationic drugs and drug
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metabolites while MRP2 and BCRP transport conjugate anionic drugs such as conjugate
glutathione [4].

The multidrug resistance phenotype
The extreme substrate variety of ABC transporter also inadvertently renders them
susceptible to a phenomenon known as multidrug resistance. Multidrug resistance is
generally characterized by over expression of ABC proteins, excessive pumping out of
therapeutic drugs and desensitization of pharmacological products in their target cells.
The primary etiology of ABC transporters-mediated is prominently expressed
transporters constantly pumping out therapeutic drugs, reducing accumulation and
efficacy of such drugs. Three ABC transporters highly expressed in the liver, the gut and
kidneys are major players in the multidrug resistance phenotypes since they govern the
bioavailability of administered therapeutic agents [4]; P-gp, MRP1 and BCRP. These
ABC proteins are structurally suited to interact with and pump out a host of structurally
diverse drugs including antimalarials, antiretrovirals and anticancer agents. The substrate
diversity of these ABC transporters is the lead cause of the multidrug resistance
phenotype in which cells overexpressing these proteins become desensitized to the effect
of many drugs simultaneously. The first multidrug resistant implicated ABC transporter
is P-glycoprotein (P-gp) [46]. P-gp is widely distributed in the apical surfaces of the
epithelial cells including the epithelial lining of the colon, pancreatic ducts, small
intestines, adrenal glands, proximal tubules the kidneys, where excretory roles are heavily
demanding. The scope of this project focuses mainly on P-gp and MRP1. Multidrug
resistance mediated by these ABC transporters are a major set-back in chemotherapy and
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this underscores the significance of discovering substrates of these ABC transporters.
Screening of anticancer agents for their interaction with ABC transporters in a timely
manner could inform withdrawal of such drugs before they reach the clinical trials stages.
The present project seeks to provide methodological alternatives to identification of
substrates of ABC transporters MRP1 and P-gp through high throughput FRET
screening.

Methodologies for evaluation of drug-ABC transporters interactions
Electron pragmatic resonance, X-Ray crystallography, cryogenic electron
microscopy, double electron-electron resonance spectroscopy, and fluorescence lifetime
imaging microscopy (FLIM) have been used to elucidate the structural dynamics and
functional significance of MRP1 and P-gp [47-51]. The limitations and inaccessibility of
most of these sophisticated techniques, for structure-function investigation cannot be
overlooked. The need for more readily available, accessible and less-expensive tools to
characterize ABC transporter proteins is crucial. Fluorescence resonance energy transfer
(FRET) is rising in prominence and fluorometer-based steady state fluorescence
spectroscopy is not only economical but also holds promise for investigation of MRP1.

Fluorescence resonance energy transfer
Fluorescence spectroscopy is a fast increasing technology which has been
harnessed for the understanding of the structure-function relationship of ABC
transporters [52]. When molecules absorb photons, they become excited and upon
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deexcitation, they release the photon of a specific wavelength. In the presence of a stable
molecule in the ground state within 100 nm of the excited molecule, the deexcitation
energy is not emitted but rather transferred to the second molecule which becomes
excited. The molecule which becomes excited first is known as the fluorescent donor
while the second molecule which absorbs the released photon is known as the fluorescent
acceptor. The inter-fluorophore distance is the distance between the fluorescent donoracceptor pair where the transfer efficiency is 0.5. It has been shown that the interfluorophore distance has a sigmoidal relationship with the transfer efficiency achieved. It
is estimated that the shorter the inter-fluorophore distance, the closer the proximity
between the fluorescent couple and concomitantly, the higher the transfer efficiency of
the donor fluorophore. The mechanism of excitation, transfer and emission of energy can
be harnessed to study the movement of proteins with in the presence of ligands. These
can shed light on the mechanism, structure and function of specific proteins such as ABC
transporters. FRET has been used to show dynamic structural changes of ABC
transporters (P-glycoprotein) using recombinant mutants and labelled fluorophores [52].
Engineering a molecular ligation of fluorescent proteins with MRP1 and coupling it with
FRET spectroscopy has also recently emerged from our group.

19

Figure 1.6 Schematic diagram showing the basic principle of fluorescence resonance energy
transfer (FRET). If an acceptor molecule in the ground state is within less than 10 nm distance
from the donor molecule, the acceptor can be excited by the energy transferred from the donor
upon de-excitation.

The rationale for the present study
A few years ago, our laboratory group produced a recombinant MRP1 biosensor
which consisted of intra-sequence cloned green and C-terminal red protein fluorophores
(green and red fluorescent proteins). This two-colorMRP1 biosensor reports dynamic
ligand-induced FRET changes as a measure of structural movements of the NBDs.
Additionally, the biosensor was a reporter of eight drug-hits which interact with MRP1,
following a screening of pool of NIH drug-like compounds [24]. In the dynamic FRET
change experiments, epifluorescence microscopy was used to image the activities and the
recombinant protein within a cell-based matrix. Fluorescence lifetime plate reader
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technology was employed for the screening protocols to evaluate the interaction of the
MRP1 biosensor with several compounds in a cell-based assay. Despite the reasonable
data generated from epifluorescence microscopy and Fluorescence lifetime projects, the
notion that the use of cells as matrix for both experiments may have slightly
compromised the purity and integrity of the fluorescence activities. Moreover, the
epifluorescence and Fluorescence lifetime technologies are sophisticated and usually
require special expertise to operate.
In the present study, our primary goals were to expand the two-color biosensor
FRET-coupled model by further seeking a FRET biosensor which is more FRET
sensitive than the precious two-colorMRP1. We engineered six MRP1 biosensors and
evaluated their FRET sensitivity in the presence of known ligands of MRP1 with the
anticipation of finding a more potent FRET biosensor. In the framework that movement
of the NBDs is related to substrate binding and catalytic activities of most ABC
transporters, we fused green fluorescence proteins and red fluorescence proteins to the
NBD-1 and NBD-2 of the transporter. The six constructs differ in the position where the
GFP protein was inserted on the NBD of the transporter. In the presence of a known
substrate at the binding pocket of the transporter, it is expected that the NBDs will draw
closer together which could elicit changes trackable by fluorescent energy transfer
technology. During the primer design and the cloning process, extreme care was taken
evade the highly conserved sequences of the NBDs.
Given that P-gp is a more important and well-characterized ABC transporter than
MRP1, we developed a FRET sensitive P-gp biosensor, useful for profiling drug
interaction with the lipid bilayer embedded protein. The mandate by the Food and Drug
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Administration of the United States of America to evaluate all drugs for their interaction
with P-gp provides rational for developing a potent P-gp biosensor which could hold
promise for high throughput screening of drugs. Using a similar cloning strategy as with
MRP1, six clones were engineered by altering the positions of the NBD-located GFP
insertion sites.

Figure 1.7 Tertiary structure of ABCC1 transporter. Showing where the green and red
fluorescent proteins were attached on the NBDs which indicate low and high FRET signal
structures. The left structure is the substrate-free open conformation and the right one is the
LTC4-bound structure. The proximal movement of the NBDs when the substrate binds, is
captured by the movement of the fluorescent pair attached to them which then translates into a
FRET signal.
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CHAPTER 2
DEVELOPMENT OF NOVEL INTRAMOLECULAR FRET-BASED MRP1
BIOSENSORS TO IDENTIFY NEW SUBSTRATES AND MODULATORS.

Abstract
Multidrug resistance protein 1 (MRP1) can efflux a wide variety of molecules including
toxic chemicals, drugs and their derivatives out of cells. Substrates of MRP1 include anticancer agents, antibiotics, anti-virals, anti-HIV and many other drugs. To identify novel
substrates and modulators of MRP1 by exploiting intramolecular FRET, we genetically
engineered 6 different two-color MRP1 proteins by changing GFP insertion sites while
keeping the RFP at the C-terminal of MRP1. Four of six recombinant proteins showed
normal expression, localization and transport activity. We quantified intramolecular
FRET using ensemble fluorescence spectroscopy in response to binding of known
substrate or ATP alone, substrate/ATP and trapping of the transporter in closed
conformation by vanadate. Recombinant MRP1 proteins GR-881, GR-888 and GR-905
exhibited reproducible and higher FRET changes under all tested conditions and are very
promising to be used as MRP1 biosensor. Furthermore, we used GR-881 to screen 40
novel anticancer drugs and identified 10 hits that potentially directly interact with MRP1
and could be substrates or modulators. Profiling of drug libraries for interaction with
MRP1 can provide very useful information to improve the efficacy and reduce the
toxicity of various therapies.
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Introduction
ATP-binding cassette (ABC) membrane proteins are a large superfamily of
proteins consisting of seven subfamilies (A to G), which mediate the ATP-dependent
transport of diverse solutes including lipids, peptides, heavy metals, ions, and a wide
variety of endogenous and exogenous compounds and their metabolites across biological
membranes [1–7]. Ubiquitously found in all phyla, ABC transporters are unidirectional
importers or exporters in bacteria, but only exporters in eukaryotes [8, 9]. When
overexpressed in tumors, ABC proteins such as P-glycoprotein (P-gp/ABCB1), multidrug
drug resistance protein 1 (MRP1/ABCC1), and breast cancer resistance protein
(BCRP/ABCG2) are implicated in poor patient response to chemotherapy. These ABC
transporters function in an ATP-dependent manner and efflux their substrate drugs out of
cells, negatively impacting the efficacy of those drugs. MRP1 can also efflux a
remarkable variety of xenobiotics and organic anions from endogenous sources, which
are mostly conjugated to glutathione, glucuronide, or sulfate [10, 11].
The prototypical functional ABC transporter is composed of four domains, two
membrane spanning domains (MSDs), each containing six transmembrane (TM) αhelices, and two nucleotide-binding domains (NBDs) that are cytosolic [12–14]. The
structure of MRP1 and several “C” subfamily members contains five domains. The two
membrane-spanning domains (MSD1 and MSD2) [15, 16] are intertwined to form the
substrate-binding site/s and the substrate translocation pathway, and an additional MSD
(MSD0) at the amino-terminus of the protein, whose specific biological function is
poorly understood [9, 17, 18]. When bound with ATP and substrate, the two cytosolic
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NBDs dimerize in a head-to-tail orientation. The energy required to translocate the
substrates is generated by the binding and hydrolysis of ATP [20–22].
Overexpression of MRP1 was reported to confer multidrug resistance in acute
leukemia, prostate cancer, breast cancer, and neuroblastoma by actively pumping out
anti-cancer agents, thereby preventing the accumulation of anti-cancer drugs, eventually
causing poor chemotherapeutic outcomes [10, 23–25]. In addition to anti-cancer agents,
MRP1 can reduce the efficacy of a wide variety of drugs commonly used for various
metabolic diseases and neurological disorders, as well as antivirals, antimalarials,
antibiotics, antidepressants, and anti-human immunodeficiency virus (HIV) drugs [1, 26,
27]. The strategic distribution of human MRP1 at “pharmacological sanctuary sites” such
as the blood–brain and blood–testis barriers, indicates the chemoprotective and tissuedefensive roles of the protein [10]. Consequently, MRP1 plays an important role in the
absorption and disposition of a remarkably diverse set of substrates across different
organs and physiological barriers [28]. The critical role MRP1 plays in health and disease
is further corroborated by its involvement in biochemical processes such as redox
homeostasis, cellular processes such as hormone secretion, and the etiology of
neurodegenerative, immunological, and cardiovascular pathologies [29–36].
Generally, drug development involves painstaking steps which include basic
research, in vitro drug screening, in vivo experimentation, preclinical stage, stage 1 to
stage 4 clinical trials, expending billions of dollars before the drug can be accessible to
the population [37]. However, a significant percentage of drugs fail in the clinical trials
due to a lack of efficacy and toxicity issues, costing billions of dollars. Profiling drug–
transporter interactions may allow discarding undesirable compounds at the very early
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stage to reduce economic burden and may avoid potential drug–drug or food–drug
interactions. Furthermore, profiling drug interactions with MRP1 can identify drugs that
are at high or low risk of developing multidrug resistance, as well as discovery of novel
inhibitors useful for clinical chemotherapy, especially in cancers where MRP1 is
overexpressed and contributes to multidrug resistance.
To investigate the structural changes of MRP1 during transport activity in live
cells, we previously engineered a two-color MRP1 construct by inserting green
fluorescent protein (GFP) and red fluorescent protein (TagRFP) at the C-terminus of
NBD1 and NBD2, respectively (Figure 1A), and quantified intramolecular fluorescence
resonance energy transfer (FRET) changes as an index of NBD conformational changes
[27]. We also used the two-color MRP1 to detect substrate/inhibitor/activator candidates
and identified eight compounds that directly interact and induce a conformational change
in the structure of MRP1 after screening of the National Institutes of Health (NIH)
Clinical Collection (NCC; a library of 446 drug-like compounds) [27]. Six of the eight
hits were later found to directly interact with MRP1 [38], while further work is needed to
verify the interaction of the remaining two hits. These findings validated the utility of the
intramolecular FRET-based approach using two-color MRP1 to identify compounds that
directly interact with MRP1. Our claim that substrate binding results in conformational
changes in the NBDs and brings them closer was further supported by recent highresolution structures of bovine MRP1 in apo and substrate-bound states (Figure 2C).
However, based on our ongoing work and our expert knowledge of MRP1
substrate specificity, we expected many more hits from screening 446 NIH drug-like
compounds. We strongly felt that many potential compounds that directly interact with

30
MRP1 were missed out in this screening due to high noise-to-signal ratio. In our proofof-concept study, we used a highly specialized fluorescence lifetime microplate reader for
high-throughput drug screening, which is not yet commercially available through an
established manufacturer. In addition, the FRET change signal upon ligand interaction
was not sufficiently high to perform screening with a more commonly used fluorescence
intensity microplate reader or a fluorometer. In order to make this innovative and
potentially transformative technology more readily accessible, economical, and
commercially more attractive, we decided to create a more efficient two-color MRP1
construct, which can produce a bigger FRET change signal upon interaction with the
substrate. Therefore, our objective in this study was to engineer several new two-color
MRP1 recombinant proteins by altering the GFP insertion site and to identify the most
efficient FRET reporter of NBD conformational changes in MRP1.
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Materials and methods
Chemicals
Nucleotides, doxorubicin, anti-GFP antibody, benzamidine, poly-D-lysine,
saponin, and 2-mercaptoethanol were purchased from Sigma Aldrich (St. Louis, MO,
USA). Estradiol glucuronide (E217βG) and sodium orthovanadate were obtained from
Santa Cruz (Dallas, TX, USA). MK571 was received from Cayman Chemicals (Ann
Arbor, MI, USA). Restriction enzymes were purchased from New England Biolabs (New
England, MA, USA) and phosphate-buffered saline (PBS) was purchased from Thermo
Scientific (Sunnyvale, CA, USA).

Engineering two-colorMRP1 constructs
All the genetically engineered two-color MRP1 proteins have a pTagRFP-N
vector as a backbone. To engineer the GR-638 construct, firstly, a C-terminal 2.6-kb
insert fragment of MRP1 which encodes amino acids 639–1531 (stop codon removed)
was generated by polymerase chain reaction (PCR) using the following primers: forward,
5’ GTA CCG CGG GGG GGC ACG AAC AGC ATC ACC G 3’; reverse, 5’ GTA ACC
GGT CT CAC CAA GCC GGC GTC TTT GGC CAT G 3’. It was cloned in frame with
TagRFP (underlined sequence is the designed restriction site). Secondly, a 0.7-kb insert
fragment which codes for GFP was amplified using the following primers: forward, 5’
GTA GTC GAC ATG GTG AGCAAG GGC GAG GAG 3’; reverse, 5’ GTA CCG CGG
CTT GTA CAG CTC GTC CAT GCC 3’. It was fused to the construct. In the third step,
an N-terminal 2-kb fragment of MRP1, which codes for amino acids 1–638, was
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amplified with the following primers: forward, 5’ GTA GAG CTC ATG GCG CTC CGG
GGC TTC TGC AG 3’; reverse, 5’ CTA GTC GAC GCC GTC TTT GAC AGG CCG
TCG CTC 3’. It was inserted in frame with GFP to generate the final construct. The GFP
sequence in the final two-color recombinant protein construct was separated from the Nterminus and C-terminus of MRP1 via amino-acid linkers, valine–aspartate and proline–
arginine, respectively. With the stop codon of MRP1 eliminated, the C-terminal end of
the protein was ligated to TagRFP, separated by a linker made of five amino acids—
threonine, glycine, leucine, alanine, and threonine.
The schematic diagram of the six engineered two-color MRP1s is shown in Figure
2.1A. A similar cloning strategy was employed to engineer five other constructs
distinguishable by the variants of GFP insertion sites. Accordingly, constructs GR-648,
GR-859, GR-881, GR-888, and GR-905 were cloned by inserting GFP after amino-acid
residues 648, 859, 881, 888, and 905, respectively, in the MRP1 protein. The primer
sequences of GFP, as well as those of N-terminal and C-terminal MRP1 fragments, are
shown in table 2.1. A schematic diagram of two-color MRP1, showing the distinctive
GFP insertion sites, is shown in Figure 2.1B. A tertiary structure representation of bovine
MRP1 in open (substrate-free) and closed (substrate-bound) conformations is shown in
Figure 2.1C.
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Figure 2.1. Schematic of two-color MRP1 structures. A- Schematic diagram of two-color
MRP1 construct showing C-terminal TagRFP and an intra-sequence GFP. B- Predicted secondary
structure of two-color MRP1 showing the three membrane spanning domains (MSD0, MSD1 and
MSD2), the two cytoplasmic nucleotide binding domains (NBD1, NBD2) and the GFP insertion
sites for engineering the constructs. The numbers 638, 648, 860, 881, 888 and 905 represent the
amino acid residue number of the wild-type MRP1 after which GFP is inserted. TagRFP is fused
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to the C-terminal of MRP1. C- Structure of bovine MRP1 in the apo (left, PDB code: 5UJ9) and
substrate bound (right, PDB code: 5UJA) condition.

Table 2.1 Primer used to clone two-color MRP1 constructs
Primer Names

Sequences (5’

3’)

MRP11–638 forward

GTA GAG CTC ATG GCG CTC CGG GGC TTC TGC AG

MRP11–638 reverse

CTA GTC GAC ATT CCT CAC GGT GAT GCT GTT CGT GCC C

MRP1639–1531 forward

GTA CCG CGG GCC ACA TTC ACC TGG GCC AGG AGC

MRP1639–1531 reverse

GTA ACC GGT CT CAC CAA GCC GGC GTC TTT GGC CAT G

MRP11–648 forward

GTA GAG CTC ATG GCG CTC CGG GGC TTC TGC AG

MRP11–648 reverse

CTA GTC GAC ATT CCT CAC GGT GAT GCT GTT CGT GCC C

MRP1649–1531 forward

GTA CCG CGG GCC ACA TTC ACC TGG GCC AGG AGC

MRP1649–1531 reverse

GTA ACC GGT CT CAC CAA GCC GGC GTC TTT GGC CAT G

MRP11–859 forward

GTA GAG CTC ATG GCG CTC CGG GGC TTC TGC AG

MRP11–859 reverse

CTA GTC GAC GTC TCG AGC CAG CAG CTC CTG GTA GG

MRP1860–1531 forward GTA CCG CGG GGC GCC TTC GCT GAG TTC CTG
MRP1860–1531 reverse

GTA ACC GGT CT CAC CAA GCC GGC GTC TTT GGC CAT G

MRP11–881 forward

GTA GAG CTC ATG GCG CTC CGG GGC TTC TGC AG

MRP11–881 reverse

CTA GTC GAC GTT CTC CTC TGC ATC CTG CTC CTG C

MRP1882–1531 forward GTA CCG CGG GGG GTC ACG GGC GTC AGC GGT
MRP1882–1531 reverse

GTA ACC GGT CT CAC CAA GCC GGC GTC TTT GGC CAT G

MRP11–888 forward

GTA GAG CTC ATG GCG CTC CGG GGC TTC TGC AG

MRP11–888 reverse

CTA GTC GAC ACC GCT GAC GCC CGT GAC CCC GT

MRP1889–1531 forward

GTA CCG CGG CCA GGG AAG GAA GCA AAG CAA ATG GAG
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MRP1889–1531 reverse

GTA ACC GGT CT CAC CAA GCC GGC GTC TTT GGC CAT G

MRP11–905 forward

GTA GAG CTC ATG GCG CTC CGG GGC TTC TGC AG

MRP11–905 reverse

CTA GTC GAC ACT GTC CGT CAC CAG CAT GCC ATT CTC C

MRP1906–1531 forward GTA CCG CGG GCA GGG AAG CAA CTG CAG AGA CAG C
MRP1906–1531 reverse

GTA ACC GGT CT CAC CAA GCC GGC GTC TTT GGC CAT G

GFP-forward

GTA GTC GAC ATG GTG AGC AAG GGC GAG GAG CTG

GFP-reverse

CTA CCG CGG CTT GTA CAG CTC GTC CAT GCC GAG AG

Cell lines and cell culture
The HEK293T (human embryonic kidney) cell line was generously donated by
Dr. Adam Hoppe (South Dakota State University, Brookings, SD, USA). Dulbecco’s
modified Eagle medium (DMEM) (GE Healthcare, Marlborough, MA, USA) enriched
with 10% fetal bovine serum (FBS) was used to grow the HEK293 cell lines. Cell lines
were grown in a humidified incubator maintained at 5% CO2 and 37 °C. This incubation
condition was retained in all subsequent cell culture procedures.

Preparation of MRP1-enriched membrane vesicles
Membrane vesicles were prepared based on the method described by Leo et al.
(1996) with minor alterations. Thawed frozen cell pellets from −80 °C were resuspended
in homogenization buffer (250 mM sucrose, 50 mM Tris-HCl, and 0.25 mM CaCl2)
supplemented with 1× protease inhibitor cocktail (enriched with 1mM
ethylenediaminetetraacetic acid (EDTA)). Cell suspension was pressurized to 450 psi in a
pre-cooled nitrogen bomb chamber for 5 min to disrupt the plasma membrane. Exploded
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cell lysates were then centrifuged at 500× g at 4 °C for 10 min. The supernatant was
collected into clean pre-cooled high-speed ultracentrifuge tubes, while the cell pellets
were re-suspended in homogenization buffer and re-centrifuged to pool the second
supernatant. The entire supernatant retrieved was layered over 35% (w/w) sucrose
complemented with 10 mM Tris-HCl and 1 mM EDTA (pH 7.4) and centrifuged at
25,000 rpm at 4 °C using a Beckman SW28 swinging bucket rotor in the Beckman
Optima LE-80K ultracentrifuge (Beckman Coulter, Brea, CA, USA) for 1 h 10 min.
About 8 mL of the opaque interface was recovered in low-sucrose buffer (25 mM sucrose
and 10 mM Tris-HCl; pH 7.4) and centrifuged again for 35 min at 25,000 rpm at 4 °C.
The supernatant was discarded, while the pellets were resuspended and washed in 1 mL
of transport buffer (50 mM Tris-HCl and 250 mM sucrose; pH 7.4) by ultracentrifugation
at 55,000 rpm for 20 min using the mini-ultra rotor in the Beckman TL-100
ultracentrifuge. The plasma membrane pellets were resuspended in transport buffer and
passed through a 27-gauge needle 20 times for vesicle formation. All centrifuges and
rotors were pre-cooled to 4 °C at least 1 h prior to respective centrifugations. The quickstart Bradford Protein Assay kit (BioRad, Hercules, CA, USA) was used to measure
protein concentration.

Two-color MRP1 expressing stable cell lines
Stable cell lines expressing two-color MRP1 constructs were prepared by
transfecting the two-color MRP1 expression plasmids into HEK293T cells using
jetPRIME mammalian transfection reagent (Polyplus-transfection SA, Illkrich, France)
following the manufacturer’s guidelines. Cultures were incubated for 24 h before
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replacing the complete DMEM with medium containing 400 µg/mL Geneticin (G418).
After two weeks of maintaining cells, the G418 concertation was doubled to 800 µg/mL.
Using flow cytometry, cells expressing both GFP and RFP were sorted from nonexpressing cells, and consequently maintained under a lower G418 selection
concentration of 200 µg/mL.

Immunoblot analysis
Lysates of HEK293 cells transfected with two-color and wild-type MRP1
expression vectors were prepared in Halt Protease Inhibitor Cocktail (ThermoFisher
Scientific, Waltham, MA, USA) supplemented with radioimmunoprecipitation assay
(RIPA) buffer. Pierce bicinchoninic acid (BCA) Protein Assay was the method of choice
for protein concentration determination. Prior to an hour-long room-temperature
membrane blocking, protein electrophoresis (20 µg of protein) was performed on 7.5%
Mini-PROTEAN® TGX™ gels and placed onto an Immobilon® polyvinylidene fluoride
(PVDF) membrane (EMD Millipore). After blocking, membranes were incubated at 4 °C
overnight using monoclonal anti-MRP1 antibody (IU5C1), or anti-α-tubulin antibody or
anti-GFP at 1:250 and 1:5000 dilutions, respectively. Incubation with a secondary
antibody was done for an hour at room temperature with horseradish peroxidaseconjugated goat anti-mouse immunoglobulin G (IgG; H+L) and target proteins were
detected using enhanced chemiluminescence substrate (PerkinElmer) and the OMEGA
LUM G imaging system (Aplegen, Pleasanton, CA, USA).
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Detection of MRP1 localization
HEK293T cells were plated and incubated in a humidified 5% CO2-supplemented
incubator at 37 °C for 24 h before being transfected with the six two-color MRP1
plasmids using jetPRIME transfection reagent (Polyplus-transfection SA, Illkrich,
France), following the manufacturer’s protocol. After 48 h of incubation, cells were
imaged with a 63× oil objective confocal microscope (TILL Photonics GmbH,
Gräfelfing, Germany). GFP and RFP were excited at 470 nm and 561 nm, respectively.
Emissions of GFP and RFP were correspondingly achieved at 496–530 nm and 573–637.
All images were processed with the ImageJ software (NIH).

Doxorubicin accumulation assay
HEK293T cells were plated at 3 × 105 cells/well in 2 mL of complete medium on
a coverslip coated with poly-D-lysine in a six-well plate and incubated in a humidified
incubator (5% CO2, 37 °C). After 24 h, the HEK293T cells were transiently transfected
with the six different two-color MRP1 constructs in separate wells using jetPRIME
mammalian transfection reagent and incubated as previously for 48 h prior to doxorubicin
treatment for 1 h. Images were taken using a confocal microscope equipped with a 63×
oil immersion objective and a 1.35 numeral aperture capacity (TILL Photonics GmbH,
Gräfelfing, Germany). GFP and Doxorubicin were excited at 470 nm wavelength using
Ar laser illumination, with emission bands of 480–530 nm for GFP and 570–605nm for
doxorubicin. RFP was excited at 561 nm with an emission band of 573–637 nm. All
images were processed with ImageJ (NIH).

39
Ensemble fluorescence spectroscopy
HEK-293 cells stably expressing GFP–MRP1 or two-color MRP1 were used to
prepare membrane vesicles. Steady-state ensemble fluorimetry was used to determine apo
and ligand-induced FRET efficiency with minor modifications in the experimental
conditions described previously [39]. Briefly, 10 µg of MRP1-enriched membrane
vesicles in Tris sucrose buffer (250 mM Tris and 50 mM sucrose; pH 7.4) were kept for 2
min at 37 °C. Membrane vesicles were then incubated with 10 µM of test compounds for
10 min at 37 °C in a water bath prior to FRET measurements. Fluorescence spectroscopy
was carried out in a 50-uL quartz glass cuvette with the Fluorimeter model FL3-11. GFP
was excited at 465 nm. Emission for GFP was recorded at 480–650 nm with 3 s of
integration time. Excitation and emission slit widths of 5 nm were used in all
measurements. Firstly, an emission scan of the GFP–MRP1 sample (donor only) was
collected while monitoring average donor emission peak. Emission scans were collected
for various two-color MRP1 constructs under different experimental conditions (apo or in
the presence of a ligand or test compound) while monitoring donor quenching, and the
average donor emission peaks were recorded. The emission scan was collected every 3 s
with an interval of 5 nm for a total of 10 min.
To calculate FRET efficiency, the relative fluorescence intensity of the donor in the
presence and absence of the acceptor was measured. The ratio of the average donor
emission peak intensity in the two-color MRP1 sample to the average donor emission
peak intensity in the GFP-MRP1 sample was subtracted from 1 to obtain the transfer
efficiency of apo and compound-induced conditions, as shown in Equation (1) [40].

40
Transfer efficiencies of compound-induced samples were normalized with that of the apo
condition to obtain the percent change in FRET.
(1 − IDA/ID) × 100,

(1)

where ID and IDA represent the intensities (counts per second, cps) of the donor and
acceptor fluorophores, respectively.

Table 2.2 Parameters for steady state fluorometry
Construct

Donor Acceptor Excitation

Emission

Excitation

Emission

wavelength

wavelength

slit

slit

nm

nm

nm

nm

GFP-MRP1

GFP

-

5

5

465

480-650

GR-638

GFP

RFP

5

5

465

480-650

GR-881

GFP

RFP

5

5

465

480-650

GR-888

GFP

RFP

5

5

465

480-650

GR-905

GFP

RFP

5

5

465

480-650

Anticancer drug-screening using fluorescence spectroscopy-based FRET approach
To validate the two-color MRP1/FRET model as a viable tool for the discovery of
potential modulators of the transporter, 40 anti-cancer drugs were screened using the
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most sensitive biosensor. Two-color GR-881 was selected as the lead biosensor based on
pre-screening results and was, therefore, used for the screening of the 40 clinically tested
anti-cancer agents (Appendix A). Firstly, 10 µg of membrane vesicles purified from
HEK293/GR-881 were preincubated for 2 min and combined with 10 µM of each of the
40 anti-cancer agents in separate reactions using Tris–sucrose buffer (TSB) as the buffer
medium. Prior to FRET measurements with Fluorimeter model FL3-11, the reaction was
incubated for 10 min at 37 °C. JNJ-38877605 was used as a negative control for the
experiments. Experiments were repeated three times independently, and the percent
FRET change was measured and reported as previously described.
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Results and discussion
Genetic engineering and expression of two-color MRP1 recombinant proteins
We previously engineered a two-color MRP1 recombinant protein that could be
utilized for high-throughput screening of drug libraries to discover unknown activators,
inhibitors, or transportable substrates of MRP1 [27]. In order to make this innovative
approach more robust and readily accessible, we decided to create new two-color MRP1
constructs, which are more sensitive to substrate interaction. To test if altering the
position of the GFP insertion resulted in enhanced FRET sensitivity, we generated six
additional two-color MRP1 constructs by inserting the GFP tag at different sites within
the MRP1 coding sequence, while keeping the RFP at the end of MRP1 (Figure 2B).
Different GFP insertion sites were chosen using our knowledge of ABC transporter
structure–function relationships, guided by the homology models of MRP1 and sequence
alignments with related transporters. The other major consideration in the design was to
avoid regions critical for the expression and function of MRP1. We chose two sites in the
loop region preceding NBD1 and four sites for GFP insertion in the loop region
connecting NBD1 to TM12. These regions are predicted to be very flexible and dynamic.
Based on available structural information for MRP1 and related ABC drug transporters,
the fused GFP and RFP tags are expected not to disrupt the binding of various substrates
to the binding site/s formed by the MSDs.
MRP1 expression was checked by immunoblot analysis using cell lysates of
HEK293 cells transfected with complementary DNA (cDNA) expression vectors
encoding wild-type or two-color MRP1, loading 10 µg of whole-cell lysate per lane. The
six newly created two-color MRP1 recombinant proteins were GR-638, GR-648, GR-
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859, GR-881, GR-888, and GR-905. GR-873 two-color MRP1 was the construct made in
our previous proof-of-concept study. Tagging MRP1 with GFP and RFP is reflected by
GR, and numbers in the name indicate the GFP insertion site. For instance, in GR-638,
GFP is inserted after residue 638 of the wild-type MRP1 sequence. Two-color MRP1
proteins were detected using anti-GFP antibody, and the immunoblot results indicated the
expected molecular mass of ~250 kDa for all new two-color MRP1 recombinant proteins,
similar to the previously characterized protein GR-873, an indication of the collective
sizes of the GFP (27 kDa), TagRFP (27 kDa), and the 190-kDa wild-type MRP1 (Figure
2.2). We demonstrated earlier that the GR-873 expression level and activity are same as
wild-type MRP1 (WT-MRP1) protein. Based on immunoblot analysis, expression levels
of GR-638, GR-881, GR-888, and GR-905 were normal and similar to GR-873, and, as
expected, WT-MRP1 was not detected with anti-GFP antibody. However, the expression
levels were moderately reduced for GR-859 and dramatically reduced for GR-648. The
insertion of GFP after residue 859 or 648 of MRP1 likely interfered with the proper
folding of MRP1 because both insertion sites were closest to NBD1, which is a highly
conserved domain in the ABC family of transporters.
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Figure 2.2 Two-color MRP1 immunoblots. Immunoblots of whole-cell lysates (10 μg)
containing wild type (WT-MRP1) and 6 two-color MRP1 constructs. Detection was by rabbit
polyclonal anti-GFP antibody (1:5000 dilution, overnight at 4 °C) and mouse monoclonal Anti-αtubulin (1:8000 dilution, overnight at 4 °C).

Localization and transport activity of two-color MRP1 proteins in live cells
Fluorescent protein tags like GFP or RFP are usually fused at the amino-terminal or
carboxyl-terminal, and do not often cause protein folding and trafficking issues.
However, insertion of GFP within the coding sequence of MRP1 could potentially cause
problems with the correct folding and trafficking of MRP1. Although all the two-color
MRP1 recombinant proteins showed the expected size, we wanted to make sure that both
fluorophores (GFP and RFP) matured properly and that the recombinant MRP1 proteins
were folded, trafficked, and localized properly at the plasma membrane of cells. HEK293
cells were transfected with cDNA expression vectors encoding different two-color MRP1
proteins, and confocal microscopy was used to visualize the localization and expression
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levels of recombinant MRP1 proteins. Confocal images in Figure 2.3 showed that all
two-color MRP1 recombinant proteins except GR-648 localized properly at the plasma
membrane. In addition, upon acquiring images using the GFP and RFP channel, and
analyzing the merged images, it was obvious that both fluorophores matured properly.
However, insertion of GFP in the GR-648 recombinant protein was not tolerated and
induced misfolding and processing defects, leading to reduced levels of the recombinant
protein, as well as intracellular retention; therefore, this construct was not included in
further investigation. The GR-859 recombinant protein showed partial mislocalization
and intracellular retention that can be attributed to the moderately reduced levels
observed in the Western blots, but the recombinant protein was predominantly localized
at the plasma membrane.
To determine if the engineered two-color MRP1 recombinant proteins were
functional, their transport activities were evaluated in live cells by measuring
accumulation of the fluorescent anti-cancer drug, doxorubicin, a well-known substrate of
MRP1 [41,42]. HEK293 cells were transfected with cDNA expression vectors encoding
different two-color MRP1 proteins, and confocal microscopy was used to visualize the
accumulation of doxorubicin (Dox) inside the cells. Images were captured for GFP, RFP,
and Dox, and images were merged for analysis. Transiently transfected cells are expected
to have a mixed population of cells, whereby some cells that pick up the vector DNA will
express two-color MRP1 while untransfected cells will not at the plasma membrane.
HEK293 cells are known to express extremely low or negligible levels of endogenous
MRP1. Confocal microscopy of transiently transfected HEK293 cells showed high
doxorubicin accumulation in the nucleus of untransfected cells, but doxorubicin
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fluorescence was very low or negligible in cells expressing either GR-638, GR-881, GR888, or GR-905 (Figure 2.4). These results demonstrate that recombinant MRP1 proteins
GR-638, GR-881, GR-888, and GR-905 were functionally active. In contrast, HEK293
cells transfected with GR-859 showed high doxorubicin accumulation in the nucleus,
indicating that this recombinant protein was not functional, despite having the expected
size and proper localization at the plasma membrane. Consequently, GR-859 was not
included in further studies.

47

Figure 2.3. Localization and expression of two-color MRP1. HEK-293 cells were plated on
glass-bottom chambered coverslips as described in Materials and Methods. Fluorescent images
were taken using a confocal microscope equipped with a 63× oil-immersion objective. GFP and
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TagRFP were excited at 470 nm and 561 nm respectively. Emission was accomplished at 480530 nm for GFP and 580-669 nm for RFP respectively.

Figure 2.4. Doxorubicin (Dox) accumulation assay. HEK293T cells were transiently
transfected with 6 different two-color MRP1 constructs and incubated for 48 hours after which
doxorubicin treatment was done. Images were taken using a confocal microscope equipped with
63× objective. GFP and Dox were excited at 470 nm wavelength using Ar laser, with emission
bands of 480-530 nm for GFP and 573-637 nm for Dox. RFP was excited at 561 nm and its
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emission was collected at 580-669 nm. Data was collected from all three different channels, GFP,
RFP and Dox.

Substrate-free FRET efficiencies of the two-color MRP1 proteins
FRET is a very useful tool to detect biochemical interactions, such as protein–
protein interactions and protein–DNA interactions, and to study protein structural
dynamics [27,43–49]. The efficiency of this nonradiative energy transfer is inversely
proportional to the sixth power of the distance between donor and acceptor fluorophores,
which makes the FRET approach extremely powerful for detecting conformational
changes within a protein. Figure 2.5A shows a graphical representation of the relationship
between FRET efficiency and the distance between the donor and acceptor fluorophores.
Our goal was to create a two-color MRP1 biosensor that produces a high FRET
efficiency change upon substrate interaction. If the intramolecular FRET efficiency of the
apo (FRET in the absence of substrate) two-color MRP1 is too low, then the FRET
biosensor protein would not be very sensitive reporter to small distance changes in the
structure of the protein (representing the bottom part of the curve in Figure 2.5A).
Similarly, if the intramolecular FRET efficiency of the apo two-color MRP1 is too high,
then the FRET biosensor protein would also not be very sensitive to small distance
changes in the structure of the protein (representing the top part of the curve in Figure
2.5A). A two-color MRP1 protein that exhibits an intramolecular FRET efficiency in the
range of approximately 30–70% is desirable, because the curve is the steepest in that
region; correspondingly, a small structural change upon substrate binding can result in a
higher FRET change from the basal level [50].
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Previously, we engineered a two-color MRP1 protein (GR-873) that reported
substrate-induced intramolecular FRET change as a function of structural changes in the
nucleotide domains of MRP1 [27]. To determine the basal intramolecular FRET
efficiencies of the new two-color MRP1 proteins, we employed steady-state fluorescence
spectroscopy using a fluorometer. To keep the protein in its native environment,
membrane vesicles isolated from HEK293 cells stably expressing different two-color
MRP1 proteins were used for the FRET experiments. As shown in Figure 2.5B,
fluorescence intensity of the donor (GFP) was highest for the GFP-MRP1 construct
(donor-only construct with no RFP). The fluorescence intensity of GFP decreased to
varying degrees in the different two-color MRP1 recombinant proteins due to donor
quenching in the presence of the acceptor, RFP. The shorter the inter-fluorophore
distance between the inserted GFP and the terminal RFP, the higher the apo FRET
efficiency of the construct. The calculated intramolecular FRET efficiency (%) for GR638, GR-881, GR-888, and GR-905 was 10.5 ± 1.5%, 66.0 ± 1.0%, 72 ± 1.0%, and 83.5
± 1.5%, respectively (Figure 2.5C). This indicates that the distance between GFP and
RFP is shortest in GR-905 and longest in GR-638. The intramolecular FRET efficiency
(%) for apo GR-873 was previously reported to be ~16%. Based on these data, GR-881,
GR-888, and GR-905 appear very promising in terms of reporting higher FRET
efficiency changes upon interaction with substrate.
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Figure 2.5. Variable ligand-free (Apo) FRET efficiencies of the two-color MRP1
constructs.
A- Graphical representation of the influence of inter-fluorophore distance on transfer efficiency.
The more proximal the fluorophores, the higher the FRET efficiency. The higher the apo FRET,
the higher the change in transfer efficiency until a certain threshold is reached. B- Fluorescence
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spectra of different two-color MRP1 proteins (GFP-MRP1 used as donor control). C-Ligand-free
FRET efficiency of different two-color MRP1 proteins. Membrane vesicles were prepared from
HEK-293 cells stably expressing different two-color MRP1 proteins (GR-638, GR-881, GR-888,
GR-905). 20 µg of each two-color protein in Tris sucrose buffer was prepared and measured for
ligand-free FRET with Fluorimeter model FL3-11 using 465 nm excitation wavelength for GFP
and 480-650 nm emission wavelength range for both GFP and RFP. Experiments were done in
duplicates and in some cases between different membrane vesicle preparation batches. Intensities
of the two-color MRP1 constructs were normalized to the donor GFP-MRP1. FRET efficiency
was calculated using the equation 1.0.

Evaluation of two-color MRP1 proteins as FRET-based biosensors
To determine the capacity of the engineered two-color MRP1 proteins as biosensors and
reporters of conformational changes in the NBDs upon substrate binding, we measured
ligand-dependent structural changes of the MRP1 protein through steady-state FRET
spectroscopy using the fluorometer. Membrane vesicles isolated from HEK293 cells
stably expressing different two-color MRP1 proteins were used for the FRET
experiments. In the presence of E217βG (a well-known physiological substrate of MRP1)
[51–53], the average FRET efficiency changes observed for GR-638, GR-881, GR-888,
and GR-905 were 0.5, 3.35, 2.25, and 2.5%, respectively (Figure 2.6). These results are in
agreement with earlier findings that reported conformational changes in the NBDs upon
interaction with substrate alone [30,39]. Different two-color MRP1 proteins also showed
a range of FRET efficiency changes in the presence of ATP alone or E217βG + ATP.
With the exception of GR-638, all the two-color MRP1 proteins produced higher FRET
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efficiency changes in the presence of E217βG + ATP compared with either E217βG or
ATP alone. This is expected because the presence of both E217βG and ATP should shift
the equilibrium toward the closed conformation of the transporter. In addition, all twocolor MRP1 proteins produced the highest FRET efficiency change when the transporter
was trapped in the closed conformation (E217βG + ATP + vanadate) and this is
consistent with the vanadate-locking phenomenon reported for other ABC transporters
[54,39]. It is important to note that our previously engineered GR-873 was not able to
show detectable FRET change in the presence of E217βG alone, whereas GR-881, GR888, and GR-905 exhibited significant FRET efficiency changes in the presence of
E217βG alone. As shown in Figure 2.6, the three two-color MRP1 proteins (GR-881,
GR-888, and GR-905) consistently produced higher FRET efficiency changes in various
tested conditions, while the highest FRET efficiency change was observed with GR-881
upon interaction with the substrate alone.
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Figure 2.6. Ligand-dependent intramolecular FRET measurements. A- Ligand-dependent
FRET changes of GR-638 protein. B- Ligand-dependent FRET changes of GR-881 protein. CLigand-dependent FRET changes of GR-888 protein. D- Ligand-dependent FRET changes of
GR-905 protein. 20 µg of protein in tris sucrose buffer was prepared and incubated with 5 µM of
E217βG and/or 4mM/5 mM ATP/MgCl2 and 1 mM sodium vanadate for 10 minutes prior to
FRET Measurements using Fluorimeter model FL3-11. GFP excitation was done at 465 nm and
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RFP at 530 nm. Emissions for GFP and RFP were collected at 480-650 nm. Experiments were
done in duplicates and in some cases between different membrane vesicle preparation batches.

Identification of Anti-cancer drugs that interact with MRP1
To further validate the two-color MRP1 protein model as a potent biosensor
system, and two-color MRP1-coupled steady-state fluorescence spectroscopy as a viable
tool for the drug screening to identify novel substrates, inhibitors, or activators of MRP1,
we screened 40-novel clinically tested anti-cancer drugs. GR-881 was chosen for this
screening because it was found to be most sensitive to substrate binding. Membrane
vesicles isolated from HEK293 cells stably expressing the GR-881 MRP1 biosensor were
used in the fluorescence spectroscopy-based FRET experiments. We screened the 40drug library at least two independent times for their interaction with the GR-881 MRP1
biosensor. Results from a single screening are presented in Figure 2.7A. Ten drugs,
whose chemical structures are shown in figure 2.8, were identified which increased FRET
and produced high and consistent FRET changes in three independent experiments
(Figure 2.7B). Means of the FRET efficiency changes observed for the identified hits
were as follows: PF-04217903 (1.75%), GDC-0879 (3%), BI-2536 (2.75%), triciribine
(2.85%), TW-37 (3.5%), axitinib (3.8%), MK-2206 (5.1%), linsitinib (9.25%), lapatinib
ditosylate (9%), and cediranib (11.75%) (Figure 2.7B). Epigallocatechin gallate (EGCG),
a known substrate of MRP1 and one of eight compounds previously identified in the
FRET-based screening, was used as a positive control and produced a mean value of
3.5% FRET efficiency change. JNJ-38877605, an anti-cancer drug which does not
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interact with MRP1, was used as a negative control, and no detectable FRET efficiency
change was observed in this case.
In the present study, using our newly engineered GR-881 MRP1 biosensor, we
identified 10 compounds that are suggested to directly interact with and induce a
conformational change in the structure of MRP1 after screening only 40 anti-cancer
drugs. The identified compounds from this screen could be substrates, inhibitors,
activators, or molecules that simply interact with MRP1 to stimulate transport of a
substrate or bind with the transporter for unknown reasons or could be a false hit due to
non-specific interaction with MRP1. Preliminary data in a related ongoing project suggest
that three of these 10 hits (triciribine, MK-2206, and cediranib) interact with MRP1, and
we plan on conducting a detailed investigation for all 10 hits to understand and confirm
the biochemical nature of their interaction with MRP1. Our results indicate that the GR881 MRP1 biosensor is a very powerful tool for identifying drugs and compounds that
interact with MRP1.
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Figure 2.7 Anticancer drug screening with two-color GR-881. A- Change in FRET efficiency
(%) for the 40 anticancer drugs from one trial. B- Ten anticancer compound-hits showed
consistently reproducible FRET changes with GR-881. FRET measurements were performed
using Fluorimeter model FL3-11. Donor excitation occurred at 465 nm and emission was
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collected within the 480-650 nm range. GFP quenching observed. The criteria for selecting the
ten hits was drugs which recorded reproducible FRET changes in independent screens. The data
is represented as mean ± SEM from three independent experiments.

Figure 2.8 Chemical structures of the ten-drug hits.
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Conclusion
We previously engineered a two-color MRP1 protein and demonstrated the proof of
concept of measuring intramolecular FRET efficiency as an index of protein
conformational changes upon ligand binding. When this recombinant protein was used in
screening a library of 446 drug-like compounds, we identified eight hit compounds (~2%
of total compounds screened). In the present study, we engineered six additional twocolor MRP1 recombinant proteins and, after detailed characterization, identified three
two-color MRP1 proteins (GR-881, GR-888, and GR-905), which report improved
substrate-induced intermolecular FRET changes as a function of structural changes of the
protein. The two-color MRP1 biosensor GR-881 was used to screen 40 anti-cancer drugs
and was able to identify 10 drugs as hits (25% of total compounds screened). The newly
engineered GR-881 has an apo FRET of 66% as compared to 16% apo FRET for the
previous construct. Based on Figure 2.5A, GR-881 falls in the middle region of the
sigmoidal curve and is expected to produce a higher FRET signal upon a certain
structural change. In addition, we think the use of MRP1-enriched membrane vesicles as
an experimental matrix instead of cells reduces the complexity of reaction matrices and
avoids nonspecific noise, thereby enhancing the overall intramolecular FRET sensitivity
in the steady-state fluorescence spectroscopy-based approach.
Traditionally, researchers focused on functional-based approaches to identify
modulators of ABC transporter proteins. For MRP1, the membrane-vesicle-based in vitro
radiolabeled E217βG uptake assay is commonly used to identify modulators [55,19].
However, MRP1 and other drug transporters are expected to have multiple distinct
substrate-binding sites. A functional assay based on quantifying transport is unable to
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detect substrates that bind to a different site and fail to compete with the test substrate.
Currently, there is no established high-throughput assay available to identify substrates of
MRP1. The idea of the intramolecular FRET-based MRP1 biosensor approach to
identifying substrates and modulators is highly innovative and transformative. This
approach could potentially be applied to other efflux transporters, and especially to ABC
proteins with no known substrate or functional assay. In addition to the discovery of
novel substrates and modulators, the two-color MRP1 biosensor protein could be used for
single-molecule FRET-based studies to understand the structural dynamics of MRP1 in
the native membrane environment. Future projects will focus on the development of a
vesicular transport coupled LC–MS/MS assay to verify the MRP1 substrate status of the
hits. We also plan on developing a two-color MRP1 fluorescent plate-reader-based highthroughput screening assay to identify more novel substrates of MRP1.
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CHAPTER 3
ENGINEERING OF TWO-COLOR P-GLYCOPROTEIN BIOSENSOR FOR
FLUORESCENCE-BASED PROFILING OF DRUG INTERACTION.

Abstract
P-glycoprotein, a member of the ABC transporter proteins, mediates the effluxtranslocation a diverse array of dissimilar solutes across plasma membranes and by an
ATP-dependent hydrolysis. The involvement of the lipid bilayer-located P-gp in tissue
defense, efficacy/toxicity of drugs and clinical MDR of antiretrovirals, anti-malignancies
and antiparasitic provides a rationale for investigating structure, function and ligands of
the transporter. Our group previously developed a two-color MRP1 biosensor by fusing
Green fluorescence protein and red fluorescent proteins with the transporter. The MRP1
biosensor detects FRET changes as an index of small movements in the domains of the
protein including the NBDs using epifluorescence microscopy. Here, we expanded the
two-color FRET model by engineering a set of six P-gp biosensors to determine which
one responds most sensitively to dynamic FRET changes. We observed that two-color Pgp, GR-678, localizes precisely in the plasma membrane, extracellularly exports
doxorubicin and is inhibited by verapamil. Consequently GR-678 was selected as the lead
biosensor for steady state FRET measurements using fluorometer model H-11, an
affordable and readily accessible instrument. Our results show that GR-678 displays
etoposide-induced percent FRET change which increases upon inclusion of ATP,
suggesting normal FRET response. In addition, we observed the highest percent FRET
change in the presence of etoposide/ATP/sodium orthovanadate. This result suggests that
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GR-678 reports vanadate trapping of hydrolytic reactions in the ADP-bound condition
which is consistent with earlier reports. GR-678 also identified six hits drugs following a
50-drug screening of NIH anticancer library. Overall, we have developed for the first
time, a FRET sensitive two-color P-gp biosensor which is useful for discovery of novel
ligands of P-gp and holds promise for high throughput profiling of direct drug-P-gp
interactions using a more economical ensemble FRET approach.

Key words: Two-color P-gp, ATP-binding cassette proteins, Multidrug resistance,
Fluorescence resonance energy transfer, Two-color MRP1, Biosensor, membrane
vesicles.
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Introduction
Adenosine triphosphate (ATP) binding cassette transporters (ABC) are a large
superfamily of proteins, many of which harness energy from ATP hydrolysis to
overcome a concentration gradient and translocate a variety of structurally unrelated
exogenous compounds from the cell [1-3]. ABC transporter genes are found in all life
forms; eukaryotes, prokaryotes, and algae encoding channel proteins, importers or
exporters [4, 5]. ABC transporters are generally composed of transmembrane domains
and intracellularly located nucleotide binding domains which are responsible for the
ATP-dependent extrusion of solutes from cells [6, 7]. One of the most important and
well-studied ABC transporters is ABCB1, also known as permeability or
phosphoglycoprotein (P-gp or P-glycoprotein).
The secondary structure of the P-gp is characterized by a pair of homologues
divides, each consisting of six-transmembrane helical-domain and a cytoplasmic
subtended nucleotide binding domain. These 12 helixes combine to form the pore which
contains an array of evolutionarily conserved sequences responsible for substrate
recognition of a diverse range of ligands [2, 8]. The extracellular side of the pore is
prominently hydrophobic while polar and charged amino acids characterize the
cytosolically-facing portion [2, 9]. The P-gp structure is conformationally malleability
which allows for multiple structural movements of its domains. This aids P-gp to discern
stereoisomeric compounds while concurrently providing multiple binding sites for many
substrates with extensive diversity. Studies of the crystal structure of mouse P-gp reveal
two conformational states of the protein; the high-substrate affinity open conformation in
which the NBSs are apart and the substrate-bound closed conformation [10, 11].

68
P-glycoprotein is pertinently expressed by immunologically active tissues and
organs because of the extreme diversity of their substrate recognition and translocation
activity [4] of the transporter. P-gp is remarkably distributed in the canaliculi of the liver
and the lumen of the small intestines where they avert the cytotoxicity of orally ingested
drugs by extracellularly pumping out these drugs. Physiologically, the 1280 amino acidlong P-gp is involved with immune responses at crucial sanctuary sites such as the bloodplacenta, blood-cerebrospinal fluid and blood-testis barriers and this underscores the
importance of the protein in tissue defense [12]. Permeability glycoprotein also plays a
key role in physiological processes required for normal brain and spinal functions such as
lipid homeostasis within the central nervous system [13, 14]. Furthermore, fetal drug
toxicity, neurological damage and several fold increase in drug influx have been reported
in animals naturally deficient in the abcb1 gene or which lack the gene by genetic
modification [15, 16].
Multidrug resistance (MDR) is responsible for over 90% of poor patient outcomes
during chemotherapy of metastatic tumors and is a key drawback in cancer healthcare
[17-19]. The170 kD P-gp is a major player in the clinical MDR phenotype.
Overexpression of P-gp in tumor and brain cells, causes significant impairment in
therapies targeting the brain, including antiepileptics, antiretrovirals and
chemotherapeutics because the protein actively excludes these drugs from the cells [20,
21]. P-gp-mediated MDR is reported to be responsible for non-responsiveness of drugs
targeting sarcoma, acute myeloid leukemia, neuroblastoma in children, and its prominent
expression is prognostic of approximately 40% failure in epilepsy treatment [22-24].
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Given that P-gp governs pharmacokinetic indices such as absorption, distribution,
metabolism, excretion (ADME) [4], mediates drug efficacy/toxicity, and is implicated in
clinical and anticancer MDR, profiling of the interaction of drugs with P-gp is
imperative. Besides, some known ligands and high-affinity substrates (cysteinyl
leukotriene and doxorubicin) of P-gp overlap with those of other ABC transporters and
this could pose hindrances to P-gp investigation. This further justifies the development of
methodological approaches and strategies to detect direct interaction of the transporter
with P-gp-exclusive ligands. A few years ago, the Food and Drugs Administration (FDA)
authorized the profiling of all drugs in clinical trials for their interaction with P-gp. This
mandate warrants the exploration of more tools and experimental approaches to
characterize ligands and modulators of P-gp.
Recently, our group engineered a two-color multidrug resistance protein 1
(MRP1) by fusing green and red fluorescence proteins (GFP and RFP) to the protein [11].
The recombinant transporter reported dynamic fluorescence resonance energy transfer
changes (FRET) changes as an index of structural movements of MRP1 using live-cell
based epifluorescence microscopy. The two-color clone further identified 8 hits following
high throughput screening of an NIH library of clinically tested drugs using Fluorescence
lifetime technology (FLIM). This two-color FRET model unlocked opportunities for high
throughput screening of ligands of not only MRP1 but also other ABC transporters.
Unfortunately, epifluorescence microscopy and FLIM technologies are advanced,
uncommon and sophisticated and require highly-skilled expertise to operate.
Here, we present a more economical and applicable two-color based-steady state
FRET approach to expand the two-color FRET model to P-gp, a more clinically
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important ABC transporter than MRP1. The goal of the present study was to engineer six
two-color P-gp biosensors by altering the position of GFP on the transporter to determine
which clone is the most FRET-sensitive biosensor using membrane vesicle-based steady
state FRET approach. The lead two-color P-gp biosensor, responded normally to dynamic
FRET changes and detected 6-hits from a 50-compound screening of anticancer library of
drugs. We anticipate that this lead FRET biosensor of the six will be a useful reporter in
high throughput profiling of P-gp-substrate interactions.
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Methods and materials
Chemicals
Nucleotides, doxorubicin, anti-GFP antibody, benzamidine, poly-D-lysine, saponin and
2-mercaptoethanol were purchased from Sigma Aldrich (St. Louis, MO). E217βG and
sodium orthovanadate were from Santa Cruz (Dallas, Texas).

Primer design and molecular cloning
The interest of our group in the two-color ATP-binding cassette transporter
proteins (ABC) model began with the engineering of a two-color multidrug resistance
associated protein-1 (MRP1) by ligating a green fluorescence protein (GFP) and red
fluorescence protein with MRP1. Essentially, the two-color MRP1 is composed of a GFP
protein sandwiched between two fragments of the MRP1 protein, upstream at N-terminal
and downstream, at C-terminal to which TagRFP is fused. Following the success of this
two-color MRP1, here, we expand the two-color biosensor innovation to include the most
important ABC transporter, P-glycoprotein, by cloning six two-color ABCB1 (1280
amino acids) vectors. The first clone to be engineered was two-color GR-642. The
cloning process was initiated by using the original two-color MRP1 clone from our
previous study [11] as the backbone vector. The N-terminal 2 kb fragment of GR-873
which codes for amino acids 1-873 was remove using the appropriate restriction
endonucleases, Sac I and Sal I. Then, by using the primers (forward, 5’ GTA GAG CTC
A TGGATCTTGAAGGGGA CCGCAATGG AGGA GC 3’ and reverse, 5’ GTA GTC
GAC AT C AGCTGCATTTT CTAA TTCAACTTCATTTCCTG 3’, restriction sites
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underlined) and through polymerase chain reaction (PCR), the N-terminal ~1.9 kb section
of the 3.8 kb long P-gp protein, encoding 1-642 amino acids was generated and ligated
in-frame into open ends of GR-873. Therefore, the GR-873 protein at this intermediary
stage consisted of the N-terminal of P-gp and the C-terminal portion of MRP1. Next, the
remnant C-terminal 2.6 kb segment of MRP1 in the intermediary GR-873 is excised
using the Sac II and Age I restriction enzymes. This detached C-terminal MRP1 fragment
was replaced through ligation with a PCR-produced C-terminal ~1.9 kb fragment of P-gp
encoding 643-1280 amino acids (stop codons removed), using the primers (Forward, 5’
GTA CCG CGG GAA T CCAAAAGTGA AATTGA TGC CTTGGAAATGT C 3’ and
reverse, 5’ GTA GTC GAC A T C AGCTGCATTTT CTAA TTCAACTTCATTTCCTG
3’, restriction sites underlined). The final product is a recombinant 2- color P-gp protein,
GR-642 in which the GFP protein is inserted at amino acid residue -642 connected to the
Val-Asp and Pro-Arg linkers at the N-terminus and C-terminus respectively. The NBDs
are predicted to make ligand-induced movements during catalytic activity, and hence
their selection as sites for the attachment of the two fluorophores during genetic
modification of the transporter. The whole process was repeated altering the GFP
insertion sites on the NBD1 to produce the other five P-gp constructs namely; GR-647,
GR-653, GR-662, GR-671, GR-678 as shown in the schematic diagram of the secondary
structure of two-color P-gp in figure 3.1A. Table 3.1 summarizes the primers designed
for the polymerization reactions of the P-gp gene. All regions of evolutionary importance
the P-gp protein were cautiously avoided during the design of the two-color P-gp
strategy. Figure 3.1B shows the tertiary structure of P-gp in the open and closed
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conformations and FRET changes are expected to occur in the presence of ligands. All
lyophilized primers were obtained from Europhins, Lancaster, PA.

Figure 3.1. Schematic representations of the structure of P-gp. A. Schematic of the secondary
structure of two-color P-gp showing the different GFP insertion sites at amino acid residues -647,
-653, -662, -671, -678 which resulted in different constructs namely, GR-647, GR-653, GR-662,
GR-671, GR-678. B. Tertiary structure of the P-gp depicted in the open (left) and closed (right)
conformations of the NBDs. (PDB code: )
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Preparation of stable cell lines
Transient transfection of the six two-color P-gp constructs into 293T cells was
performed with jetPRIME (Polyplus-transfection SA, Illkrich, France) mammalian
transfection reagent and following the manufacturers’ protocol. The cells were allowed to
grow for 24-hours before being rid of complete DMEM to prepare them for
aminoglycoside antibiotic treatment. The removed complete DMEM was replaced with
400 µg/ml of geneticin- G418, for antibiotic selection of recombinant gene-expressing
cells. Cultures were incubated for a fortnight prior to doubling the G418 concentration to
800 µg/ml. Flow activated cell sorting was performed to select cells expressing both GFP
and RFP from non-expressing ones. After flow cytometry, the GFP and RFP expressing
cells were maintained under 200 µg/ml geneticin.

Western blot analysis of two-color P-gp
293T cells were transfected with the different two-color P-gp plasmids in a 2:1
ration with jetPRIME transfection reagent. Halt Protease inhibitor (ThermoFisher
Scientific, Waltham, MA) and RIPA buffer (ThermoFisher Scientific) were used in
combination to prepare protein lysates of the cells. Protein concentration was determined
using BCA protein assay (ThermoFisher scientific). After the protein assay, 20 µg of the
protein lysates was used to perform SDS-PAGE electrophoresis before an hour-long
membrane-blocking step was accomplished on 7.5% Mini-PROTEAN® TGX™ gels
(BioRad, Hercules, CA) and transferred onto an Immobilon® PVDF membranes (EMD
Millipore). Four degrees centigrade incubation of membranes was conducted with
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primary antibodies, polyclonal anti-GFP or mouse monoclonal anti α-tubulin (Sigma
Aldrich, St. Louis, MO) at dilutions of 1:5000 and 1:250 respectively. Membranes were
incubated with horseradish peroxidase goat anti-mouse secondary antibody (IgG,
ThermoFisher scientific) for one hour prior to detection of proteins with OMEGA Lum G
using chemiluminescence substrate (PerkinElmer, Waltham, MA). Wild type pTC-P-gp
(TransOmic Technologies Inc, Huntsville, AL) and non-transfected 293T cells were used
as controls.

Membrane localization and doxorubicin transport activity
Firstly, 293T cells transfected with vectors containing different two-color P-gp
plasmids using jetPRIME transfection reagent (Polyplus-transfection SA, Illkrich,
France) were plated on cover glass in 25 mm 6-welll plates. The plated cells were then
incubated at 370 C for 48-hours in humidified 5% CO2 incubator. After 2-days, images
were taken using a confocal microscope equipped with a 63× oil-immersion objective
(TILL Photonics GmbH, Gräfelfing, Germany. GFP was excited at 470 nm and emitted
within the 496 nm-530 nm range, while RFP was excited at 561 nm with emission bands
of 573-637 nm.
Two-color P-gp-expressing 293T cells were plated on poly-D-lysin-coated 6-well
plates containing cover slips at 3 x 105 cells/well and incubated for 48-hours under
similar conditions as described above. At the inception of drug treatment, complete
DMEM was removed and replaced with a medium containing 10 µM Doxorubicin in
0.2% DMSO and incubated for 2-hours prior to imaging with the confocal microscope.
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Doxorubicin was excited at 470 nm and emitted at 570-605 nm. GFP and RFP
wavelengths were maintained as before.

Effect of verapamil on two-color Pgp-dependent doxorubicin transport
To ascertain if a known P-gp inhibitor will foil the efflux-transport of
doxorubicin, 1 ml of 25 µM of verapamil was added to the 293T/two-color P-gp cells and
removed after 30 minutes. DMEM medium containing another 25 µM of verapamil or
DMSO were added to the 293T/two-color P-gp cells, in combination with 10 µM
doxorubicin and incubated for 2 hours. The confocal microscope was used to observe the
effect of verapamil on the ATP-dependent translocation of doxorubicin by the two-color
P-gp biosensors. Experiments were performed concurrently with the doxorubicin-only
treatment accumulation assay.

Preparation of membrane vesicles
Preparation of vesicular plasma membranes was performed using the method
described previously by [25] with modification. Frozen two-color P-gp expressing cells
dissolved in phosphate buffer saline were briefly thawed and dissolved in a hypotonic
homogenizing buffer (250 mM sucrose, 50 mM Tris-HCl, 0.25 mM CaCl2, pH 7.4)
containing 1x protease inhibitor tablets (supplemented with 1 mM EDTA, Santa Cruz
Biotechnology, Santa Cruze, CA). To disrupt the plasma membranes, cells were
subjected to 450 psi pressure in a nitrogen chamber on ice for 5 min, prior to
centrifugation at speed and temperature of 500 x g and 40 C for 10 minutes (Sorvall
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legend X1R centrifuge, ThermoFisher). The supernatant was pooled, and the cell pellets
were re-dissolved in the 10 ml homogenizing buffer for a second round of 10-minute
centrifugation. The collected supernatant was layered over high sucrose buffer (35%
W/W sucrose, 10 mM Tris-HCl, and mM EDTA; pH 7.4) and ultra-centrifuged at 25000
rpm, 4 °C for 1 hour using a pre-cooled Beckman SW28 swinging bucket rotor in the
Beckman Optima LE-80K ultracentrifuge (Beckman Coulter, Brea, CA). The plasma
membrane portion which settled within the middle portion of the centrifuge tubes were
carefully pipetted out and dissolved in low sucrose buffer (25 mM sucrose, 10 mM TrisHCl, and mM EDTA; pH 7.4) for a second cycle of ultracentrifugation as before, only
this time for 45 minutes. The plasma membrane pellets were salvaged and resuspended in
1 ml of Tris sucrose buffer (TSB) (250 mM sucrose, 50 mM Tris-HCl, pH 7.4), prior to a
4 0C, 20-minute ultracentrifugation at 55000 rpm in the Beckman TL-100 ultracentrifuge
(Beckman Coulter, Brea, CA). A 27-gauge syringe was used to create membrane vesicles
by passing the resulting pellets through it for about 20 cycles.

Fluorescence resonance energy transfer measurements
Membrane vesicle isolated from 293T cells prominently expressing the only
functional two-color P-gp biosensor, GR-678 was used for fluorescence spectroscopy
experiments. The Fluorimeter model FL3-11 (HORIBA Edison, New Jersey) was used to
acquire all FRET measurements. First, two reactions were set up; the compound mix tube
and the membrane vesicle tube. The compound mix reaction consisted of Tris sucrose
buffer (TSB) (250 mM sucrose, 50 mM Tris-HCl, pH 7.4), 20 or 50 uM-compound under
investigation and/or 4 mM/5 mM ATP/MgCl2. 20 µg of membrane vesicles and the
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compound reaction were separately pre-incubated at 37 0C for 5- minutes prior to ligandbinding initiation. After pre-incubation, the compound reaction was mixed with the
membrane vesicles and further incubated for 10 minutes at 37 0C to allow respective
ligands to bind to the protein. Ligand-free condition in which no ligands, except TSB was
included in the compound mix was prepared as control reaction and was also mixed with
membrane vesicle. Since the two-color P-gp clones contained both GFP and RFP, a
previously cloned GFP protein was used as the donor-only condition. The donor-only,
prepared in the same way as the two-color vesicles, was collected into a 50 µL quartz
cuvette, inserted in the FL3-11 model fluorometer and excited at 465 nm. Emission for
the donor was monitored at 480nm to 650 nm using an integration time of 3s which
yielded a specific intensity of the donor emission. Next, the cuvette was rinsed with
buffer and the two-color P-gp ligand-free condition was loaded and measured for the
GFP intensity. The intensity of the GFP in the ligand-free condition was normalized with
the intensity of the GFP in the donor-only condition to generate a FRET efficiency for the
apo condition of GR-678 using equation 1. The compound condition of two-color GR678 was then measured while monitoring donor-quenching. The normalized donor (GFP)
intensity of the ligand-free condition was subtracted from the normalized donor intensity
of the ligand-induced condition to generate the percent (%) change in FRET the twocolor biosensor.
(1 – I DA/ ID) * 100

(1)

Where ID is donor intensity in the donor-only condition (counts per second, cps) and I
DA is the donor intensity in the donor-acceptor or two-color condition.
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Anti-cancer drug screening
A set of 50 anticancer library of compounds were screened using fluorescence
spectroscopy as described above and the two-color GR-678 as the sole biosensor reporter.
There were 50 compound conditions in this case with each compound repeated twice. As
before, normalizing the apo condition FRET efficiency with the ligand-induced condition
transfer efficiency results in the percent change in FRET efficiency. In each case of the
duplicate FRET measurements, 20 µM of compounds and 20 µg of GR-678/293T
membrane vesicles were used.
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Results and discussion
P-glycoprotein ATP-dependently exports a broad spectrum of hydrophobic
substrates against concentration gradient across plasma membranes. Consequently,
predominant expression of P-gp is responsible for the acquisition of the MDR phenotype
by a plethora of infectious diseases and tumor cells; a major obstacle in chemotherapy [7,
26] . Clinical MDR is characterized by the desensitization of cells to the effect of drugs
due to energetic transport-efflux of these drugs out of cells by certain ABC transporter
proteins, most prominently, P-gp [7]. A widely used anticancer agent and a notable
substrate of P-gp, doxorubicin has recently been found to be more potent against
hepatocellular carcinoma when used in combination with sorafenib [27]. Sorafenib was
reported to significantly decrease the mRNA expression of P-gp [28]. The need to
circumvent tumor MDR by withdrawal/discontinuation of culprit-anticancer agents or by
combination-therapy with inhibitors, provide justification for identification of anticancer
substrates of P-gp. The clinical importance of P-glycoprotein and the mandate by the
FDA for profiling of drug interactions with P-gp have created opportunities for expansion
in method developments targeted at novel P-gp ligand/substrate discovery.
Here, we present for the first time a recombinant two-color human P-gp biosensor
which reports intramolecular FRET changes as a measure of structural changes in the
transporter. This novel P-gp biosensor also identified six anti-cancer drugs which have
direct interaction with the transporter, following a screening of 50 drug library of
anticancer agents using steady state FRET. This P-gp biosensor model draws on the
methodology and success of the two-color MRP1 biosensor our group recently
engineered. The two-color MRP1 which demonstrates fluorescence sensitivity as a
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function of conformational movements, was cloned by joining GFP and RFP proteins
intra-sequence with the protein.

Expression and transport activity of two-color P-gp
Molecular cloning was employed to engineer six two-color human P-gp
constructs. The constructs were genetically modified by sandwiching GFP protein in
between two halves of the P-gp protein with TagRFP attached downstream of the Cterminal. To determine if the two-color P-gp proteins are immunologically active, we
used anti-GFP antibodies to carry out immunoblot assay. Our results in figure 3.2 show
that all six two-color P-gp constructs were expressed at ~210 kD size but only GR678/293T showed an intense band. Combining the weighs of the ~170 kD permeability
glycoprotein [3] with the ~27 kD weights each of GFP and RFP proteins, justifies the
detection of the two-color P-gp via GFP at ~210 kD. The other five clones showed
waning bands, suggesting an impairment in expression level of those two-color P-gp
constructs. Regardless, the presence of faint or intense bands indicate the presence of the
GFP cloned into the two-color P-gp constructs. The non-transfected parental 293T cells
and the wild-type pPCT-Pgp/293T lanes were empty, an indication of the absence of
GFP. The anti-α-tubulin antibody used detected the presence of α-tubulin, an endogenous
housekeeping globular protein which validates the results of our immunoblot assay.
To determine if genetically modifying human P-gp by incorporating a fluorescent
pair intra-sequence compromises the membrane localization and functionality of the Pgp, we transiently transfected 293T cells with the two-color P-gp plasmids. Using
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confocal microscopy, we observed the plasma membrane trafficking of the two-color Pgp. Our results in figure 3.3 show that the localization of GR-643, GR-647, GR-652, GR662, and GR-671 are smudged at the plasma membrane but GR-678 appear to traffic
normally to the plasma membrane. This result is consistent with the blotting data from
figure 3.2 which show GR-678 as the only properly expressed protein with an intense
band. Our observations suggest that of the six dual-color P-gp recombinant clones, only
GR-678 is precisely expressed and localized in the lipid-bilayer. The inserted GFP appear
to be in undesired locations which do not support appropriate trafficking and/or
maturation of the other constructs.
Doxorubicin accumulation assay was conducted on all six clones to investigate
the functional activity of the biosensors. Doxorubicin is a commonly used
chemotherapeutic drug for combating non-Hodgkin and Hodgkin lymphoma, acute
lymphoblastic leukemia, breast cancer, ovarian carcinoma, bone carcinoma and a host of
other malignancies [27]. The fluorescent doxorubicin doubles as a promiscuous substrate
of P-gp and other ABC transporters and well-suited for testing transport activity of twocolor P-gp. Our results in figure 3.4 showed doxorubicin was absent from 293T cell
populations transfected with GR-678 but remained inside the nuclei of untransfected
cells, after 2 hours of 10 µM doxorubicin treatment. However, there was hardly any twocolor P-gp transfected cells detected in plasma membrane of the 293T cells supposed to
expressing the other two-color constructs, nor was doxorubicin extruded out of the cells.
These results suggest that GR-678 is a functional protein and shows no negative effects
of molecular cloning. Our results also confirm the observation of impaired membrane

83
localization and concomitantly non-functionality of all the other recombinant proteins
except GR-678.
Extensively characterized as an inhibitor of P-gp, verapamil has been shown to
increase the area under the plasma drug concentration versus time curve (AUC) of
doxorubicin when both drugs were administered to rodents [29, 30]. To unequivocally
corroborate the functional activity of the two-color P-gp clones especially GR-678, we
further explored the effect of 25 µM of verapamil on the doxorubicin efflux by the
genetically modified transporters. We observed that in the presence of verapamil, twocolor GR-678 failed to efflux doxorubicin as the drug remained in the nuclei of 293T
cells expressing the two-color protein as shown in figure 3.5. This result is consistent
with established report of inhibition of the extrusion of doxorubicin by verapamil [29]
[31] and further enforces our notion that GR-678 is a normally functional transporter.
Following the results of western blot, localization and functional experiments, only the
purportedly functional GR-678 was selected as lead biosensor in all downstream FRET
procedures.
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Figure 3.2. Western blot of two-color P-gp constructs. Ten (10) μg of whole cell lysates of
non-transfected 293T, wild type 293T/pTCP-P-gp, and all six 293T/two-color P-gp were
prepared. SDS-PAGE electrophoresis was performed after which antibody detection was done by
rabbit polyclonal anti-GFP antibody (1:5000 dilution, overnight at 4 °C). The endogenous
control, alpha tubulin was detected by mouse monoclonal anti-α-tubulin (1:8000 dilution,
overnight at 4 °C).
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Figure 3.3. Localization of two-color P-gp in 293T cells. 293T cells were plated on cover glass
and transfected with vectors containing different two-color P-gp constructs (GR-642, GR-647,
GR-653, GR-662, GR-671 and GR-678). After 48- hours, images were taken with confocal
microscope equipped with a 63× oil-immersion objective. GFP and tagRFP were excited at 470
nm and 561 nm, respectively. GFP and RFP emissions were achieved at 495-530 nm and 573-637
nm respectively.
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Figure 3.4. Doxorubicin transport activity by two-color P-gp biosensors. 293T ells were
transiently transfected with the two-color plasmids, GR-642, GR-653, GR-662, GR-671 and GR678 and incubated for 48 hours. At the inception of compound treatment, DMEM medium was
pipetted out and replaced with 1 ml medium containing 10 µM doxorubicin for 2 hours prior to
imaging with the confocal microscope.
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Figure 3.5. Effect of verapamil (vera) on doxorubicin efflux by two-color P-gp. To determine
the effect of verapamil on doxorubicin transport by two-color P-gp, 293T cells were transfected
with the two-color P-gp vectors and incubated for 48 hours. Next, the total transfection medium
was removed and replaced with a medium consisting of 25 µM verapamil for 30 minutes. This
medium was also pipetted out and discarded to be replaced by another medium made up of 25
µM verapamil or DMSO and 10 µM Doxorubicin and incubated again for 2 hours. The
concentration of DMSO was kept at 0.2%. confocal microscope equipped with 63× objective was
used to take images. GFP and Dox were excited at wavelength of 470 nm using Ar laser. RFP
was excited at a wavelength of 561 nm. The emission band of 496-530 nm was used for GFP,
573-637 nm for RFP and 570-605 nm for Dox.
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Two-color P-gp responds normally to dynamic FRET changes
FRET spectroscopy is a prominent technique for exploring structural movements
of macromolecules which provide useful insights into structure-function mechanisms. We
performed FRET spectroscopy to determine the ligand-induced structural dynamics of
purified membrane vesicles of 293T/GR-678. Two-color P-pg, GR-678 was FRET-tested
with ATP alone, etoposide alone, and sodium orthovanadate in the presence and absence
of the nucleotide, ATP/ MgCl2. The DNA synthesis-targeting anticancer medication,
etoposide, used to treat testicular cancer, lung cancer and neuroblastoma
(ncbi.gov/etoposide 2004) is also a known P-gp substrate [32], It is expected that
etoposide will induce proximity of the NBDs leading to increased percentage change in
FRET efficiency relative to the ligand-free condition. FRET of the GFP donor was
measured and normalized to the FRET of the ligand- free two-color P-gp. Our results
show a ~1.5% increase in FRET efficiency for etoposide-induced two-color GR-678
compared with the ligand-free apo FRET. Upon the inclusion of ATP/MgCl2, there was a
further increase of ~1.5% change in the FRET efficiency of GR-678 representing a total
of ~2.5% when normalized with the apo FRET. To verify the vanadate trapping reportage
of the two-color GR-678, FRET was measured in the presence of sodium orthovanadate
alone and etoposide/ATP/sodium orthovanadate. Our results show about ~1% increase in
FRET of GR-678 in the presence of sodium orthovanadate alone while a high FRET
change (~4%) was displayed in the presence of etoposide/ATP/sodium orthovanadate
normalized with the apo FRET. These observations are consistent with the previously
reported dynamic FRET response by P-gp [3] using P-gp mutants labelled with Alexa
488 (donor) and Atto 610 (acceptor).
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It has been established that sodium orthovanadate or beryllium fluoride, when
introduced into an ATP-catalyzed reaction, replaces inorganic phosphate to stabilize the
ADP-bound hydrolytic stage [33, 34]. This phenomenon, referred to as vanadatetrapping, represses the ATPase catalysis and sustains the closed conformational state of
the NBDs. This scenario is in tandem with our results shown in figure 6 as we observed
the highest percent FRET change upon addition of ATP/sodium orthovanadate to the
etoposide-induced GR-678 membrane vesicle reaction. JNJ which failed to demonstrate
any signal in experiments from a previous study [35] by our group involving fluorescence
spectroscopy, ligand transport and flow cytometry, was included as negative control. JNJ
was unresponsive to dynamic FRET changes as shown in figure 3.6.
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Figure 3.6. Normal FRET responses of two-color P-gp, GR-678. A. Spectral representation of
the FRET responses of GR-678 in the presence of well-established ligands of P-gp. B. Histogram
depiction of the ligand-induced FRET changes of GR-678 in the presence and absence of
nucleotide, ATP/MgCl2. 20 µg of 273T cell-line membrane vesicles overexpressing two-color Pgp GR-678 were reacted with 20 µM etoposide, 4 mM ATP, 50 µM vanadate and 20 µM JNJ.
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The % FRET efficiencies of ligand-induced conditions were normalized with the ligand-free
condition to generate % FRET changes.

Two-color P-gp biosensor, GR-678 identifies six ligands in anticancer screening
P-gp mediated MDR is a major hindrance to therapy for various malignancies
predominantly because chemotherapeutic drugs are frequently pumped out of tumor cells
overexpressing the transporter. Here, using the two-color P-gp, GR-678 as the functional
biosensor reporter, we screened 50 anticancer drugs from a pool of a clinically tested
library. FRET efficiency from ligand-free GR-678 was subtracted from the drug-induced
transfer efficiencies to obtain the percent FRET changes recorded for each drug as shown
in figure 3.7A which represents data from one of two independent trials conducted. Six
anticancer hit-drugs which displayed consistent percent FRET changes between the two
independent screening experiments were identified as hits as shown in figure 3.7B. They
are, the EGFR-inhibiting axitinib [36], the aurora kinase-inhibitor AT9283 [37], the
survivin-targeting YM155, the Sirtuin 1-activating SRT1720 [38], the ZEB-1 genetargeting mocetinostat and the B-cell lymphoma 2 (Bcl-2)-obstructing TW-37. Notably,
all the hit drugs whose chemical structures are also presented in figure 3.8, are still at
different stages of clinical trials. Interestingly, all the anti-malignancy hit-drugs displayed
a higher FRET signal compared to the etoposide-induced (positive control) FRET
change, indicating they have stronger interaction with the phosphor-glycoprotein
transporter than does etoposide. Axitinib showed ~3%, AT9283 and mocetinostat showed
~4%, YM155 and SRT1720 showed about ~6 and TW showed the highest FRET change
(~7%) compared to apo FRET. TW-37 is a small molecule inhibitor of the Bcl-2 family
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of proteins. Interestingly, combination therapy with TW-37 and verapamil, a P-gp
inhibitor has been reported to reverse paclitaxel resistance in esophageal carcinoma [39].
This, together with the observation that TW-37 is a ligand of P-gp from the present study
may provide clues the drug needs to be a subject of investigation for precise interaction
with the transporter protein. The hit drugs are at best ligands or potential modulators of Pgp and further investigation is recommended to ascertain their actual interactive indices
with the transporter. Our group is currently developing a vesicular transport assay-based
LC-MS/MS method to unambiguously confirm the six hit drugs as substrates or
otherwise of P-gp.
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Figure 3.7 Screening of anticancer-library of drugs with two-color P-gp GR-678. 20 µg of
isolated 293T/GR-678 membrane vesicles were added to 20 µM of each compound to initiate
FRET signal reactions and incubated for 10 minutes at 370 C. The % FRET efficiencies
calculated for the drugs were normalized with the transfer efficiency of the ligand-free apo FRET
to obtain the percent changes in FRET for all drugs. A. Summarizes one independent screening
experiment of the 50 anticancer compounds using two-color P-gp GR-678 through fluorescence

94
spectroscopy. B. Percent FRET changes of the six anticancer drug-hits identified by GR-678
using ensemble FRET spectroscopy. FRET changes of the six hits were higher than of the
positive control, etoposide, a known substrate of P-gp. JNJ was included as a negative control
anticancer drug as it showed consistent non-responsiveness to functional and FRET changes in
previous experiments.
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Figure 3.8. Chemical structures of the six chemotherapeutic drugs detected as hits.
The hits were detected following steady state FRET screening of NIH clinically tested
compounds. All drugs are currently under clinical trials. Axitinib targets.
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Conclusion
Overall, we report for the first time the development of a two-color P-gp (GR678) biosensor which does not only demonstrate intramolecular FRET capabilities as a
function of structural changes in the transporter but also useful for identifying ligands of
P-gp. We have optimized and improved the initial two-color MRP1 model by using
membrane vesicles based steady state fluorescence. The two-color GR-678 P-gp
biosensor could be a vital tool for high throughput screening of drugs which directly
interact with the transporter using plate reader spectroscopy. Our two-color P-gp
biosensor-based ensemble FRET assay provides an eminent alternative for research
entities investigating compounds which interact directly with P-gp. Considering the
affordability and accessibility of the fluorometer model H-11, our two-color P-gp
ensemble FRET method offers a powerful and readily available substitute to more
sophisticated FRET technologies in investigating the structure-function of P-gp. Research
groups interested in developing biosensor models and bioengineering technologies should
benefit from the two-color P-gp model presented here. Future expansion of our two-color
model will include strategic site-directed mutagenesis to enhance FRET capability of the
recombinant P-gp biosensor.
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Table 3.1 Primer used to clone two-color P-gp constructs

Primer Names

Sequences (5’

3’)

Pgp1–642 forward

GTA GAG CTCA TGGATCTTGAAGGGGACCGCAATGGAGGA GC

Pgp 1–642 reverse

GTA GTC GACA T C AGCTGCATTTT CTAA TTCAACTTCATTTCCTG

Pgp 643–1280 forward

GTA CCG CGG GAATCCAAAAGTGA AATTGATGCCTTGGAAATGT C

Pgp 643–1280 reverse

GTA ACC GGT CTCTGGCGCTTTGTTCCAGCCTGGACACTG

Pgp 1–647 forward

GTA GAG CTCA TGGATCTTGAAGGGGACCGCAATGGAGGA GC

Pgp 1–647 reverse

GTA GTC GAC TT CACTT TTGGA TTCAT CAG CTGCATTTTCA

Pgp 648–1280 forward

GTA CCG CGG ATTGATGCC TTGGAAATGT CTTCAAATGA TTCAAG

M Pgp 648–1280 reverse GTA ACC GGT CTCTGGCGCTTTGTTCCAGCCTGGACACTG
Pgp 1–653 forward

GTA GAG CTCA T GGATCTTGAAG G GGA CCGCAATGGAGGA GC

Pgp 1–653 reverse

GTA GTC GAC CATTTCCAAGGCATCAATTTCACTTTTGGATTCAT

Pgp 654–1280 forward

GTA CCG CGG T CTT CAAATGA TTCAAGAT CCA GT CTAATAA GAAA

Pgp 654–1280 reverse

GTA ACC GGT CTCTGGCGCTTTGTTCCAGCCTGGACACTG

Pgp 1–662 forward

GTA GAG CTCA TGGATCTTG AAGGGGACCGCAATGGAGGA GC

Pgp 1–662 reverse

GTA GTC GAC CATTTCCAA GGCATCAATTTCACTTTTGGATTCAT

Pgp 663–1280 forward

GTA CCG CGG T CTTCAAAT GA TTCAAGAT CCAGTCT AA TAA GAAA

Pgp 663–1280 reverse

GTA ACC GGT CTCTGGCG CTT TGTTCCAGCCTGGACACTG

Pgp 1–671 forward

GTA GAG CTCA TGGATCTTGAAGGGGACCGCAATGGAGGA GC

Pgp 1–671 reverse

GTA GTC GAC ACTCCTACGAGTTGATCTTTTTCTTATTAGACTGG

Pgp 672–1280 forward

GTA CCG CGG GTCC GTG GATCACAAGC CCAAGA C AGA AAGCTTAG

Pgp 672–1280 reverse

GTA ACC GGT CTCTG GCGCTTTGTTCCAGCCTGGACACTG

Pgp 1–678 forward

GTA GAG CTCA TGGATCTTGAAGGGGACCGCAATGGAGGA GC

Pgp 1–678 reverse

GTA GTC GAC T TGGGCTTGTGATCCACGGACACTCCTACGAGTTG

Pgp 679–1280 forward

GTA CCG CGG GACAGA AAGCTTAGTA CCAAAGAGGC TCTGGATGA
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Pgp 679–1280 reverse

GTA ACC GGT CTCTGGCGCTTTGTTCCAGCCTGGACACTG

GFP-forward

GTA GTC GAC ATG GTG AGC AAG GGC GAG GAG CTG

GFP-reverse

CTA CCG CGG CTT GTA CAG CTC GTC CAT GCC GAG AG
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CHAPTER 4
RELEVANT CONTRIBUTIONS
Scope
This chapter catalogues relevant contributions which the current project made to the
general goals of our research group. These are side projects which impact other scholarly
activities in our research group. The projects described in this section are categorized into
three. One of the projects relates to discovery of twelve clinically tested anticancer drugs
from a high throughput screening using high-content imaging. The second project relates
to determination of the effects of vitamin D analogues on MRP1 transcript. The third
project concerns the discovery of eighteen inhibitors of MRP1 which were identified
predominantly using doxorubicin as a fluorescent substrate probe. Firstly, we expound
the use of two-color multidrug resistance associated protein-1 (MRP1) engineered in our
lab to show that MRP1 inhibitor hits discovered by our lab directly interact with the
transporter. The fluorescence resonance energy transfer technique was used to evaluate
the interaction of the twelve hits with the two-color recombinant biosensor. Next, we
show how reverse transcriptase-quantity polymerase chain reaction (qPCR or RT-PCR)
was used to determine the effect of vitamin D analogues, calcitriol and calcipotriol on the
mRNA of MRP1. The qPCR experiments were carried out to support or contradict the
data obtained from western blot in which the effects of the calcitriol and calcipotriol on
the MRP1 protein were investigated. In the third and final project, eighteen MRP1
inhibitor hits following high content screening with doxorubicin of anticancer library of
compounds. These hits had been further evaluated as MRP1 inhibitors with flow
cytometry, doxorubicin accumulation assay via confocal microscopy and shown reversal
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of cytotoxicity. We designed a project to determine the effects of the eighteen-test
compound-hits on the mRNA of MRP1. We also assessed the interactivity of the drug
hits with MRP1 by using the purified membrane vesicles expressing GR-888 biosensor,
engineered in the current project in a fluorescent spectroscopy approach.
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Two-color MRP1 biosensor-based FRET detects direct interaction of twelve MRP1
inhibitors with the transporter.

Introduction
Recently, our research group developed a high content method for identification of novel
inhibitors of multidrug resistance associated protein-1 (MRP1). The high content method
discovered twelve inhibitor hits of MRP1 following screening of clinically tested
anticancer library of drugs. The initial high throughput screening which found the hits
used calcein green as the fluorescent MRP1 substrate reporter. Interestingly, of the twelve
potent inhibitors, two (cyclosporin A and rapamycin) are well-established inhibitors of
MRP1 and ten are novel; tipifarnib, AZD1208, deforolimus, everolimus, temsirolimus,
HS-173, YM201636, ESI-09, TAK-733, and CX-6258 [1]. Next, the hits were validated
as true MRP1 inhibitors using several different functional assays.
First, doxorubicin accumulation assay was performed in the presence of the
inhibitor-hits to determine if the hit-drugs would obstruct the efflux-extrusion of
doxorubicin by MRP1 using HEK cells overexpressing GFP-MRP1, a 1-color
recombinant MRP1 engineered by our group. Using confocal microscopy for imaging,
the assay proved the inhibitor hits impeded the normal function of MRP1 by ensuring the
accumulation of doxorubicin in the nuclei of the cells. The potency of the small
molecules as inhibitor-hits of MRP1 was further confirmed by flow cytometry, vesicular
transport using radiolabeled (E217βG and LTC4) of MRP1 as reporter. In both assays,
the twelve hits showed as potent inhibitors of the transporter under investigation, MRP1.
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While reviewers found the study well-researched with appropriate techniques and assays
to report our findings, they cited one concern. All assays reported showed the twelve hits
are true hits of MRP1 but failed to show the drugs had direct interaction the transporter.
On the other hand, it is established that in all the three major types of inhibition,
competitive, noncompetitive, and uncompetitive, one thing is mutual. Competitive
inhibition occurs when the inhibitor shares a similar chemical structure with the substrate
and competes for the same active site with the substrate. In this case the inhibitor binds
only to the free enzyme (figure 1). In noncompetitive inhibition, the inhibitor does not
resemble the substrate structurally and binds to both the enzyme and the enzymesubstrate complex. However, the inhibitor in uncompetitive inhibition only binds to the
enzyme-substrate complex and does not share structural similarities with the substrate
(Figure 4.1)[2]. In all three instances of enzyme-inhibition, the common theme is that the
inhibitor must directly bind to the enzyme to be able to enact its inhibitory efficacy on it.
This may have been the rationale behind the request to demonstrate that the twelve MRP1
inhibitor-hits directly interacts with the transporter. ABC transporters are ATPases
(enzymes which hydrolyze ATP) and they thrive on catalytic hydrolysis to perform their
efflux functions [3-5]. It is expected that ABC transporters submit to the general rule of
direct interaction of inhibitors with enzymes.
In the present project, we designed a strategy to address the reviewers’ comments.
The two-color MRP1 biosensor engineered by our group and coupled with fluorescence
spectroscopy displays dynamic FRET changes in the presence of ligands of the reporter.
This is an indication that the two-color biosensor is useful for detection of direct
interaction with MRP1. To address the concern posed by reviewers, we used the one of
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the FRET sensitive two-color MRP1 biosensors engineered by our research group to
evaluate the interaction of the twelve hits with MRP1.

Figure 4.1. Schematic diagram of the types of enzymatic inhibition.
In competitive inhibition, the inhibitor shares similar structural characteristics with the substrate
and competes with the substrate for the same active site. In non-competitive inhibition, the
inhibitor is structurally dissimilar from the substrate and binds to the enzyme at a site different
from where the substrate binds. Like non-competitive inhibitor, in uncompetitive inhibition, the
inhibitor doesn’t resemble the substrate but here, the inhibitor binds only to the enzyme-substrate
complex [10].
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Methodology: Steady state fluorescence spectroscopy
Previously, a two-color MRP1 biosensor had been genetically engineered in our lab by
fusing a green fluorescent protein (GFP) and a red fluorescent protein (RFP) to the
transporter. This genetically modified two-color MRP1 reported ligand-induced steadystate fluorescence resonance energy transfer (FRET) change [6]. Membrane vesicles of
GFP-MRP1 (donor control containing only GFP without RFP) and two-color MRP1
(acceptor) were purified from human embryonic kidney (HEK-293) cells stably
expressing either proteins. Steady-state fluorimetry was employed for ligand-free (apo)
and ligand-induced FRET analysis using experimental conditions described by [7] with
modification. Membrane vesicles (10 µg) in Tris sucrose buffer (250 mM Tris, 50 mM
sucrose, pH 7.4) was prepared and pre-incubated for 10 minutes at 370 C. Membrane
vesicles were then incubated with 10 µM of test compounds for 10 minutes at 370 C in a
water bath prior to FRET measurements. Ensemble fluorescence spectroscopy was
carried out in a 50 µL quartz glass cuvette using the Fluorimeter model FL3-11
(HORIBA Edison, New Jersey). GFP excitation was observed at 480 nm and RFP, at 530
nm. Emission for both GFP and RFP with integration time of 3 seconds was recorded at
480-650 nm. One emission scan of the donor only (GFP-MRP1 sample) was first
collected while monitoring average donor emission peak. Another emission scan was
collected in the apo condition (ligand-free two-color MRP1); donor quenching was
monitored, and the average donor emission peak was recorded. The test compound
conditions were similarly scanned, and donor quenching monitored. Each emission scan
was collected at an interval of 5 nm every 3 seconds for a total of 10 minutes. Two
independent experiments were performed in technical triplicates.
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Results and Discussion
The relative fluorescence of the donor in the presence and absence of the acceptor
was used to analyze data. The ratio of the average donor emission peak intensity (in
counts per second, cps) in the donor-acceptor sample (two-color MRP1) to the average
donor emission peak intensity in the donor only control (GFP-MRP1)) was subtracted
from one to obtain the transfer efficiency of apo and compound-induced conditions.
Transfer efficiencies of compound-induced samples were normalized with that of the apo
condition to obtain the percent change in FRET. The standard deviation of triplicates was
calculated for each test compound condition and the results, presented as mean ± SEM.
FRET spectroscopy was performed to investigate test compound-induced changes
in FRET efficiency of MRP1. The concept of donor quenching in FRET analysis, as
reported by Lakowicz in 1999 [8] is an established method for calculating the transfer
efficiency of an ensemble. The ratio of average donor intensity (cps) in the two-color
MRP1 (apo or test compound induced) samples to donor intensity in the GFP-MRP1
sample deducted from unity represents the transfer efficiency of the specific two-color
MRP1. Percent change in FRET efficiency was calculated by subtracting the transfer
efficiency of apo condition from transfer efficiency of test compound conditions. MK571, a widely known MRP1 inhibitor showed an 8% increase in FRET efficiency relative
to the apo condition. JNJ, which in previous functional assays conducted by our group
failed to show inhibitory activities against MRP1 from doxorubicin efflux, showed no
change in FRET efficiency. All test compounds showed increase in FRET efficiency in
comparison to the apo condition. Tipifarnib showed the smallest FRET change (2.4%)
and Deforolimus, the largest FRET change (9.67%) (Figure 4.2).
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All twelve test compounds demonstrate varying degrees of compound-induced
intramolecular FRET changes in two-color MRP1 through fluorescent spectroscopy,
suggesting they all directly interact with the MRP1. A known MRP1 inhibitor, MK-571
used as a positive control showed similar trend of FRET change as the test compounds
confirms the finding they are candidate-inhibitors of MRP1. Having failed previous
inhibitor test assay, negative control JNJ showed no change in FRET efficiency,
indicating the validity of the steady state FRET assay.
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Figure 4.2. Compound induced conformational changes in MRP1. Membrane vesicles were
prepared from stable HEK293/GFP-MRP1 and HEK293/two-color MRP1 cells. Membrane
vesicles (10 µg) were incubated with 10 µM of each test compound for 20 minutes at 37 °C prior
fluorescence spectroscopy using Fluorimeter model FL3-11. GFP excitation was accomplished at
480 nm and RFP was excited at 530 nm. Emission for both GFP and RFP with integration time of
3 seconds was recorded at 480-650 nm. GFP excitation was observed at 480 nm and RFP, at 530
nm. Emission for both GFP and RFP was collected at 480-650 nm with 3-seconds integration
time. Data is represented from two independent experiments in triplicates. MK571 and JNJ26854165 were used as positive and negative controls, respectively. To calculate the change in
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FRET efficiency for test compound conditions, the basal apo FTRET efficiency was subtracted
from the compound-induced FRET efficiencies and results are presented as Mean ± SEM [1].
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The effects of calcitriol and calcipotriol on mRNA levels of MRP1
Introduction
Our research group previously cloned a two-color MRP1 which reports changes in
intramolecular FRET as a function of structural conformations of the protein. The
recombinant protein also identified eight potential substrate hits of MRP1 during a high
throughput screening of National Institute of Health library of drugs [6]. The compounds
included antioxidants such as EGCG and hyperoxide, vitamin D analogue, calcitriol and
calcipotriol, anti-inflammatory mesalamine, antibiotic, meropenem, antiparasitic
nitazoxanide and antipsychotic droperidol. The results from the wide screening was not
conclusive about the substrate or inhibitor status of the eight hit compounds. The
compounds were at best considered ligands or potential modulators of MRP1. This left
room for further characterization of the hit drugs for their specific interactive index with
MRP1. To do this, functional assays were performed to determine if the hit drugs
inhibited MRP1 efflux of doxorubicin and calcein in H69AR/MRP1 and HEK/MRP1 cell
lines. The results showed that of the eight, only the vitamin D analogues, calcitriol and
calcipotriol demonstrated inhibitory activity towards MRP1 [9] (Tan et al, 2018).
Vesicular transport assay using tritium-labelled substrate of MRP1 confirmed the strong
inhibition of MRP1 by calcitriol and calcipotriol. Following the new find that these
vitamin D metabolites are strong inhibitors of MRP1, we sought to understand the effect
of these drugs on the mRNA and protein expression of MRP1. The rationale for this
research is that an inhibitor of MRP1 which also depresses the expression of the MRP1
transcript could be a more potent inhibitor than one which increases the expression
significantly. The methods which follow, were designed and executed in response to
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reviewers who raised the query about the effect of calcitriol and calcipotriol on MRP1
mRNA and protein expression. Only data from the mRNA expression experiments are
shown here as it has direct correlation with the broader perspective covered by the current
project.
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Methodology: RNA Isolation and real-time RT-PCR analysis
Approximately 106 cultured MRP1-over-expressing HEK and AR cells treated with either
DMSO, 1 µM or 10 µM calcitriol, or 1 µM or 10 µM calipotriol were pelleted by
centrifugation and stored for RNA isolation. Cultured parental HEK and H69 were
included in experiments as MRP1-non-expressing negative controls. Total RNA was
isolated from the cells using the Ambion TRIzol plus RNA purification kit (Thermo
Fisher Scientific, USA). To rid the freshly prepared total RNA of possible DNA
contamination, DNase1 enzyme treatment was performed using the Turbo DNA-free kit
(Life technologies, U.S.A.). The concentration and integrity of RNA was determined
using the 260/280 ratios generated by a Nano-drop U.V. spectrophotometer. cDNA
synthesis was done with the recombinant M-MuLV-based ProtoScript II First strand
cDNA synthesis kit (New England Biolabs Inc., MA, U.S.A.) using 1µg of the total RNA
as starting material. Gene-specific primers were designed using the Primer3 software via
Pubmed and synthesized by Europhins U.S.A. Table 1 shows the list of primers
sequences and their corresponding amplicon lengths. Numbers inserted in parenthesis in
columns three and four of table 1 represent region in gene template where primers anneal
to. The syber green dye-based Luna universal qPCR master mix (New England Biolabs
Inc., MA, U.S.A.) was used to perform quantitative PCR analysis. Total reaction-mix of
20 µL was prepared consisting of 2 µL of cDNA (20 ng/ µL), 10 µL of Luna universal
qPCR master mix (New England Biolabs Inc., MA, U.S.A.), 1 µL of primer mix and
made up to maximum volume with 7 µL of Nuclease-free water. The Quantstudio3 Realtime system (Thermo Fisher Scientific) was used for the qPCR analysis. The three-step
PCR conditions used are as follows chronologically: 950 C denaturation for 1.2 minute,
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45 cycles of (annealing at 600 C for 20 seconds, extension at 720 C for 30s), and
denaturation for 10 seconds. This was followed by melting curve stage from 600 C to 950
C for 20 seconds while scanning for fluorescence. Relative quantitation was performed
using the 2 -∆∆Ct method and data was normalized against housekeeping genes, β-actin
and ubiquitin conjugating enzyme (UbCE) of respective samples. The relative messenger
RNA (mRNA) expression level was calculated as a percentage of the both reference
genes. After qPCR, 0.9% agarose gel electrophoresis was used to verify lengths of
amplicons.
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Results and Discussion
The effect of calcitriol and calcipotriol at concentrations of 1 µM and 10 µM on the
MRP1 transcript in H69AR/MRP1 and HEK/MRP1 cells were evaluated through RTPCR. The average cycle threshold (Ct) values of target protein, MRP1 after qPCR were
normalized with those of endogenous controls ubiquitin conjugating enzyme and β-actin.
1 µM of calcitriol and calcipotriol did not significantly affect the transcription of MRP1
either in HEK/MRP1 or H69AR/MRP1 cell lines. The results showed however, that in
HEK/MRP1 cells at 10 µM, calcitriol slightly increased the relative expression of MRP1
transcript by 1.5-fold, while 10 µM calcipotriol displayed the same expression fold as the
DMSO control reaction. In H69AR/MRP1 cells however, the transcript expression of
MRP1 in the presence of calcitriol dwindled significantly by 0.5-fold while calcipotriol
had a 1.6-fold expression on mRNA of the protein (figure 3). DMSO showed no effect on
the mRNA of MRP1 or on the endogenous controls in both HEK and AR cells. The
parental H69 and HEK cells showed the least amount of mRNA expression which is
consistent with normal MRP1 expression of cells which have not been prior induced to
overexpress the protein. The two metabolites of vitamin D, calcitriol and calcipotriol also
did not have any effect on the expression of the mRNA of the housekeeping genes,
ubiquitin conjugating enzyme and beta-actin. Our results suggest that calcipotriol does
not significantly influence the mRNA expression of MRP1, whereas calcitriol
significantly reduced the expression of the MRP1 transcript only in AR/MRP1 cells. This
observation could be because of cell specific effect and may not be considered that
calcipotriol generally causes a decline in MRP1 expression. These results of qPCR
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experiments are consistent with the western blotting quantification data (not shown in the
present document).

Figure 4.3 Relative expression of MRP1 mRNA in the presence of calcitriol and calcipotriol.
A. HEK and H69AR cells were treated with 10 µM of calcitriol and calcipotriol. Calcitriol
significantly reduces the mRNA expression of MRP1 in H69AR cells but has no effect on HEK
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cells. Calcipotriol on the other hand has no significant influence on the MRP1 transcript. B. HEK
and H69AR cells were treated with 1µM of calcitriol and calcipotriol. At 1µM, none of the drugs
had any significant effect on the MRP1 transcript. All cycle threshold values were normalized to
those of the housekeeping genes used as endogenous controls. The test compounds results were
normalized with the DMSO results [9].

Table 4.1 Primer sequences and amplicon lengths
Gene

Genbank

Forward primer

Reverse primer

number
MRP1

β-Actin

length

NM_004996.

AGGACACGTCGGAACAA

GGAAGTAGGGCCCAAAGG

3

GTC

TC

(915-934)

(1151-1132)

CATGTACGTTGCTATCC

CTCCTTAATGTCACGCACG

AGGC

AT

(393-413)

(642-622)

NM_001101

Amplicon

Ubiquiti

NM_001282

ATGCGGGACTTCAAGAG

AAAATGACCGCGTTCCACA

n CE

161.1

GAG

C

(273-292)

(360-341)

237

250

88
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Detection of direct interaction of the eighteen doxorubicin hits with MRP1

Introduction
Following a mass screening of clinically tested anticancer compounds using high content
microscope, eighteen drugs were discovered as preliminary inhibitor-hits of MRP1.
These compound-hits were confirmed as true using quantitative approaches, the flow
cytometry and other qualitative means, confocal microscopy. ABC transporters like
MRP1 are ATPases which utilize ATP hydrolysis to transport a host of structurally
divergent substrates. Apart from substrates which interact with ABC proteins including
MRP1, compounds which inhibit their function must also associate with the protein one
way or another. Being ATPases, MRP1 acts like enzymes and as inhibitors must interact
with the enzymes they impede, inhibitors of MRP1 must operate in a similar fashion.
Discovery of the eighteen compounds as inhibitors of MRP1 using a myriad of wellestablished functional assays does not complete the story of the study. It was imperative
to prove that the eighteen compounds directly interact with MRP1. To validate that the
eighteen compounds directly interact with MRP1, we designed a membrane vesicle-based
fluorescent spectroscopy screen of the drug hits using two-color GR-888, developed in
the present study, as the probe.

118
Methods
The methods used to accomplish the evaluation of the interaction of the eighteen
compound hits with MRP1 are outlined in (25) without any modifications. Isolated twocolor GR-888-expressing membrane vesicles were prepared and reacted with test
compounds at 370 C FRET measurements using the fluorometer. FRET was measured in
the presence and absence of test drugs and the difference of FRET efficiency between
these two conditions was calculated as percent FRET efficiency change. Each trial was
repeated three times and the triplicate results were combined as reporter as mean ± SEM
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Results and discussion
Fluorescent spectroscopy was used to evaluate the direct interaction between the
eighteen inhibitors discovered with MRP1. In the presence of an inhibitor, movement of
the NBDs on which are located the intramolecularly inserted fluorescent-pair, GFP and
RFP. The dynamism of the NBDs is detected as a fluorescent signal and interpreted as
FRET efficiency which is subtracted from the basal FRET condition to generate values of
FRET efficiency change. Two-color GR-888 displayed different degrees of percent
FRET efficiency changes in the presence of the eighteen doxorubicin hits as shown in
figure 4.4. Our results suggest that all eighteen compounds directly interact with MRP1
with altering degrees of strength. Notably, eleven of the drugs show higher percent FRET
efficiency changes (~7-9%) compared with the FRET change of MK-571 (~5%), a
known MRP1 inhibitor used here as a positive control. JNJ, which usually shows no
signal in previous functional assays, displayed almost no FRET change, validating our
results.
We have developed a two-color ABC transporter biosensor based-FRET
technique which constitutes a standard routine protocol in the detection of direct
interaction of inhibitors and substrates with ABC proteins. Our method developed can be
mirrored by researchers interested in understanding the mechanism of interaction
between diverse types of proteins particularly receptor proteins and their ligands.
Fundamental questions of receptor-ligand associations could be answered by
incorporating our FRET-based approach.
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Figure 4.4. FRET analysis of eighteen anticancer compounds. 20 µM of each compound was
added to 10 µg of two-color MRP1 GR-888 expressing HEK membrane vesicles and incubated at
370C. GFP emission and quenching was translated to FRET efficiency. Excitation and emission
for GFP were 465 nm and 480-530 nm respectively.
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Effect of eighteen doxorubicin inhibitor–hits on MRP1 transcript
Introduction
The eighteen compounds identified through a variety of functional assays as inhibitors of
MRP1 were further evaluated for their effects on the transcription of the MRP1 gene.
Determination of how a drug influences mRNA expression requires the use of
quantitative PCR. The rationale for performing qPCR is that a MRP1 inhibitor which
additionally impedes the expression of MRP1 mRNA is more desired as a potent
inhibitor than drugs which inhibit only function of MRP1 but not its expression.

Method
Methods used for conducting qPCR including primer design, RNA isolation, cDNA
synthesis are the same as described previously. HEK cells overexpressing MRP1 were
treated with 1 µM of each drug and lysates were prepared which were divided into two
for RT-PCR and western blot purposes.

Results and discussion
Our results show that only 5 of the eighteen drugs at 1 µM significantly increased MRP1
mRNA expression by 2-fold or more. The ability of these five drugs to prominently
improve the mRNA expression of MRP1 could work against their inhibitory properties.
These results need to be substantiated with further experiments. The rest of the drugs did
not significantly affect mRNA expression as they showed slightly above or below 1-fold.
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Notably, Sarcatinib showed a 0.5-fold decrease of mRNA expression of MRP1. These
results are consistent with western blotting data (not shown here) which evaluated the
effect of the same drugs on the protein expression of MRP1. Our results suggest that
Sarcatinib may be the most potent inhibitor overall due to its ability to not only affect the
protein function but also dwindle the transcript of MRP1 gene. Further downstream tests
may be necessary to confirm these findings.

Figure 4.5 effect of test compounds on the mRNA transcript of MRP1.
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CHAPTER 5
FINAL DISCUSSIONS
MRP1 and P-gp are two of the most important ABC transporters which play a
significant role in the disposition and efflux-translocation of a variety of compounds and
therapeutic agents in an ATP-dependent hydrolysis, while mediating tissue defense of
sanctuary sites such as the blood-testis barrier, as shown through mice studies [1-5]. The
prominent expression of MRP1, P-gp along with BCRP in leukemias, breast cancer and
other tumors confers multidrug resistance (MDR) to anticancer agents, leading to poor
patient outcomes during chemotherapy [1, 6]. Therefore, profiling of the interaction of
these important transporters with pharmacological agents is imperative but the absence of
a high-throughput assay for the identification of substrates of these ABC proteins remains
an impediment to extensive drug screening. In our previous study, we developed a twocolor MRP1 biosensor which reports intramolecular FRET efficiency as a measure of
conformational changes in the presence of E217βG and other ligands. This recombinant
reporter (GR-873) also identified eight compounds including the antibiotic nitazoxanide
and the flavonoid EGCG, through a high throughput screening of a library of clinically
tested drugs using Fluorescence lifetime technology.
In the present study, to enhance the sensitivity of the 2-color-FRET model and expand it
to other ABC transporters, we cloned a set of six two-color MRP1 and P-gp proteins by
altering the locations of the GFP on the transporters. The strategic goal of the study was
to investigate which of the two-color constructs through steady state FRET, would
exhibit better FRET sensitivity than GR-873. We employed the most FRET-sensitive
two-color biosensor in fluorescence spectroscopy to identify novel modulators/ligands of
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MRP1 and P-gp. Here, we report that two-color MRP1(GR-881)- and to some extent,
GR-888 and GR-905 and two-color P-gp GR-678, is more FRET sensitivity than GR-873
and hold promise for high throughput screening and identification of novel substrates of
the two most important ABC transporter proteins.
Molecular cloning is a robust technique which has over the years, enhanced
investigation of several biological processes and has led to an immense understanding of
the genetic basis of several diseases [7]. However, genetically modifying membrane
proteins could compromise their functionality and proper localization in the plasma
membrane. In the present study, using molecular cloning, we engineered the 27 kD GFP
and the similarly 27 kDa TagRFP into the MPR1 and P-gp proteins and verified some of
the recombinant proteins properly localize in the plasma membrane. We have shown that
one P-gp and four MRP1 and constructs localize in the plasma membrane which
contradict earlier suggestions of intracellular localization of MRP1 [8]. Doxorubicin, a
common chemotherapeutic drug with a broad-spectrum efficacy against solid tumors
such as small cell lung cancer, leukemias and breast cancer [9, 10] is also a fluorescent
substrate of MRP1. Our engineered two-color MRP1 biosensors (except GR-859) and
two-color P-gp, GR-678, evacuate doxorubicin, suggesting these clones are as functional
as the wild-type transporters. Our data essentially supports a widely reported
phenomenon that clinical MDR mediating ABC efflux pumps such as MRP1, P-gp and
BCRP extrude doxorubicin out of the cell, diminishing the intracellular concentration of
the drug [11-13]. Furthermore, two-color P-gp GR-678 mediated export of doxorubicin
was inhibited verapamil, a well-known P-gp inhibitor, confirming the functionality and
utility of our engineered clone.
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The utilization of Fluorescence resonance energy transfer (FRET) in
understanding the structure and mechanism of biomolecules and bioprocesses has gained
prominence over the years [14-19]. Generally, the relationship between FRET efficiency
and the distance between the two fluorescent protein pair is characterized by a sigmoidal
curve [20]. This curve is steepest at its midpoint ~0.5 or 50% and provides insights that a
reporter which functions within the 40-60% region is anticipated to exhibit large ligandinduced FRET changes [21]. This phenomenon forms the bedrock of the present study to
find a new two-color biosensor from the set of four with an apo FRET efficiency closer to
or slightly above ~50%. The two-color MRP1 (GR-873) from our previous study showed
a ligand-free FRET of ~17% [11] using the cell-based epifluorescence microscopy assay.
However, two-color MRP1 biosensor GR-881 and two-color P-gp, GR-678 with basal
FRETs of ~63% and ~70% respectively, close to our desired range were anticipated to
demonstrate larger and more consistent compound-dependent FRET change than GR-873
in downstream experiments. These clones were consequently chosen as lead biosensors
for subsequent FRET testing. We speculate that the use of membrane vesicles, other than
live cells, provided a purer matrix which significantly compensated for the sub-sensitivity
of the fluorometer and consequently better FRET signal was shown in the present study.
Interestingly, for MRP1, we observed that the more proximal the inserted GFP in the
NBD1 is to the TagRFP in the NBD2 position, the higher the ligand-free transfer
efficiency of the two-color proteins. Our data is consistent with the already known notion
of sigmoidal relationship between inter-fluorophore distance and FRET efficiency [21].
We, however do not rule out the fact that FRET efficiency is not only influenced by
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positional dynamics of the protein pair but also by their orientational fluorophore
dynamics [14].
Estradiol-D-17β-Glucuronide (E217βG), a conjugated metabolite of the
endogenous estradiol, is a widely known substrate of MRP1 [22-24]. E217βG-alone
induced a stronger FRET signal in two-color MRP1, GR-881 and GR-888 and etoposideinduced FRET change in GR-678 was appreciable; these indicate we have developed a
more powerful tool than GR-873 [11], useful for identifying substrates of MRP1.
Vanadate trapping is a process where sodium orthovanadate prolongs ATP-hydrolytic
signal in the ADP condition [25], a phenomenon which was confirmed in a-2012 FRET
study of P-gp mutants [26]. The highest FRET change was displayed upon inclusion of
E217βG + ATP + vanadate to two-color MRP1 or etoposide + ATP + vanadate while
vadadate-alone barely showed any FRET signal. These observations are consistent with
the vanadate trapping model earlier reported. Our data does not only indicate that the
two-color MRP1 biosensors portray vanadate-locking of ATP but also suggest that the
recombinant biosensors also demonstrate normal FRET responses to known ligands.
To further validate the two-color ABC transporter model, MRP1 GR-881 twocolor P-gp GR-678 were selected as lead biosensors and used for steady-state FRET
screening of 40 to 50 anticancer drugs. In the MRP1 screening, ten drugs were identified
based on their reproducible display of FRET changes consistent with or higher than
FRET changes of the positive control EGCG, were determined as hits and ligands of
MRP1. Notably, none of the 10-compound hits were discovered as hits from a recent
study by our group, which identified 12 calcein green-probed inhibitors of MRP1 from a
high throughput screening of the same anticancer drug-pool using high content high and
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confirmed by vesicular transport and flow cytometry among tools [27]. We propose that
these 10-hits could be ligands or possibly potential substrates of MRP1. The insulin
receptor inhibitor, Linsitinib is the only drug of the ten still under clinical trials. In a
recent study of the effect of anticancer agents including linsinitib, rapamycin and JNJ38877605, linsinitib did not inhibit cell proliferation [28]. It is however unclear if MRP1
mediated MDR was partly responsible for this observation and further tests are therefore
warranted. On the other hand, the P-gp screening of 50-anticancer agents yielded 6-drug
hits. Interestingly two drugs, TW-37 and Axitinib were found as common hits from the
MRP1 and P-gp screenings. This suggests an earlier notion that some ABC transporters
particularly MRP1, BCRP and P-gp share common ligands, substrates and inhibitors.
The two-color MRP1 (GR-881) and P-gp (GR-678) are improvement of the
original two-color MRP1 GR-873 are better suited for profiling of pharmacological
interactions with the transporters. GR-881 identified 10 out of 40 drugs as hits while P-gp
detected 6 out of 50 drugs as hits. These represent 25% and 12% respective FRET
sensitivities of the recombinant biosensors. Considering that the earlier two-color
biosensor (GR-873) detected 8 out of 446 drugs screened with fluorescence lifetime plate
reader, representing just 1.8% detectability, we think the ABC biosensors developed
under this current project are more powerful and reliable tools for drug profiling to
identify substrates.
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Conclusion
Overall, we have engineered and validated two-color biosensors GR-881 (MRP1) and
GR-678 (P-gp), which reports improved intermolecular FRET changes as a function of
structural changes in response to interactions with substrates or ligands. GR-881
biosensor has further identified ten of forty and GR-678 biosensor, six out of fifty
clinically tested anticancer agents as potential ligands of the respective transporters.
These biosensors and hold promise for use in high throughput screening for detection of
drug-ABC transporter interactions and identification of substrates of the proteins.
By using isolated membrane vesicles and a steady state fluorimeter-based approach, we
have not only improved the initial two-color MRP1 model but also made it an economical
and a more accessible tool for profiling of direct interaction of ligands with MRP1. The
original two-color MRP1 GR-873 biosensor was coupled with epifluorescence
microscopy and fluorescence lifetime plate reader in cell-based assays. Here we have
harnessed the purity and less complexity of membrane vesicle matrix coupled with the
appreciable sensitivity of the steady state fluorometer to economize the two-color model
without compromising quality.
Based on the FDA mandate to test all therapeutic drugs bound for clinical trials to be
tested for their interaction with P-gp, there are several approaches being incorporated for
such testing in most pharmaceutical industries. Most approaches use the vectoral,
monolayer transport assay using the human epithelial colorectal adenocarcinoma (Caco-
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2) or the Madin-Darby Canine Kidney (MDCK) cell lines. These approaches are
laborious and time-consuming. We anticipate that our two-color ABC transporter coupled
steady state FRET will find great alterative the pharmaceutical industries interested in
characterizing substrates of P-gp and MRP1.
Researchers studying biosensors of ABC proteins and other biological processes will
benefit from our two-color FRET model by incorporating our strategy. LC-MS/MS
method for eight compounds has been development with promising results with pure
molecules. Future projects will focus on development a vesicular transport coupled LCMS/MS assay to verify the substrate-status of the hits. We also plan to develop a twocolor MRP1 fluorescent plate reader-based high throughput screening assay to identify
more novel substrates of MRP1.
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Future direction
Vesicular transport-coupled LC-MS/MS method development for identification of
substrates of ABC transporters
Following the discovery of eight potential substrate-hits for MRP1 from our
previous study, 10-hits of MRP1 from the present study and 6 P-gp ligands also from the
present study, it was imperative to confirm the true status of the interaction of these hits
with their transporters. All drugs discovered are at best potential modulators of their
transporters without a strong claim that they are substrates. We planned out to develop a
standard protocol which combines transport and an analytical technique to analyze the
transported drugs. After unsuccessful trials with high performance liquid chromatography
(HPLC) mainly due to coelution of analytes with ATP, we resorted to LC-MS/MS as the
analytical tool. The HPLC-coupled ultraviolet light (UV) analysis could not detect the
signal in the presence of drugs or was not sensitive enough. The diagram in figure 5.1
represents a calibration curve generated from measurement of pure E217βG. First, we
placed our attention on the 8 MRP1 hits from our previous study [11]. We developed LCMS/MS methods for the 8 compounds which showed desired signal peaks at the expected
elution times. We achieved good standard calibration curves following analysis of the 8drugs in their pure states. Figure 2 shows calibration curves for pure EGCG and
calcipotriol as well as graph of peak area and elution times.
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In the future, there are two anticipated tracks for this project. First is the use of
membrane vesicle-based transport assay followed by analysis of the transported drugs
using the established LC-MS/MS methods. The alternative technique is a cell-based
transport assay prior to analysis with LC-MS/MS method. These approaches will be
useful to determine the actual mode of interaction of drug-hits discovered in our lab with
ABC transporters, MRP1 and P-gp and others under study. The future perspectives could
also shed more light on the mechanisms of interactions. These are potentially powerful
tools to unequivocally determine substrates of the ABC transporters under investigation.

Figure 5.1 Data showing the standard calibration curve of different E217βG using HPLC.
Mobile phases of 80:20 ethanol and water were used as mobile solvents and wavelength of 246
nm was used to detect test compound, E217βG.
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Figure 5.2 LC-MS/MS analysis of standards and calibration of pure calcipotriol and
EGCG. Method development for compounds to detect potential substrates of MRP1 following
vesicular transport assay and LC-MS/MS analysis. A. Peak height versus elution time of pure
calcipotriol at different concentrations. B. Standard calibration curves of pure calcipotriol. Mobile
phase A: 0.1% Ammonium hydroxide, Mobile phase B: 100% methanol for calcipotriol in a
buffer medium of 80:20 methanol/NH4OH. Parent molecular ion mass of 411 in multiple reaction
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monitoring (MRM) transitions of 395.3 and 343.2 for product ions upon fragmentation.
Electrospray ionization was employed with negative polarity. Flow rate used was 1.0 ml/min. C.
EGCG peak height against elution time at variable concentrations. D. Calibration curves EGCG
standard concentrations. For EGCG, the following LC-MS/MS experimental conditions were
employed: Mobile phase A: water/0.1% formic acid, mobile phase B: 100% Acetonitrile/0.1%
formic acid at a flow rate of 0.6 ml/min. Negative ionization was used with single reaction
monitoring parameter masses of 457 to 169 product ion for EGCG. 80:20 of mobile phase A and
B was used infusion buffer.
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Appendix A
List of the 50 anticancer drugs FRET-screened with GR-881 and GR-678
ABT-263 (Navitoclax)

Entinostat (MS-275 SNDX-275)

Afatinib (BIBW2992)

SB 431542

PD0325901

SU11274

Trichostatin A (TSA)

KU-55933

BMS-599626 (AC480)

LY294002

AUY922 (NVP-AUY922)

XL147

Brivanib (BMS-540215)

Saracatinib (AZD0530)

PF-04217903

Dovitinib (TKI-258)

BI 2536

Lenalidomide (Revlimid)

TW-37

Sunitinib Malate (Sutent)

Mocetinostat (MGCD0103)

Elesclomol

SRT1720

GDC-0941

YM155

MK-2206 2HCl

MLN8237 (Alisertib)

Linsitinib (OSI-906)

AT9283

GDC-0879

Andarine (GTX-007)

Triciribine (Triciribine phosphate)

AZD6244 (Selumetinib)

Axitinib

CI-1040 (PD184352)

Cediranib (AZD2171)

Motesanib Diphosphate (AMG-706)

Lapatinib Ditosylate (Tykerb)

Tandutinib (MLN518)

STF-62247
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ABT-888 (Veliparib)

Nutlin-3

Bosutinib (SKI-606)

SB 216763

Imatinib Mesylate

Refametinib (RDEA119 Bay 86-9766)

Sorafenib (Nexavar)

Rucaparib (AG-014699 PF-01367338)

VX-680 (MK-0457 Tozasertib)

JNJ-38877605

